{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "A\u03b2", "BAN2401", "aducanumab", "amyloid precursor protein", "tau"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32824102", "DateCompleted": {"Year": "2021", "Month": "02", "Day": "18"}, "DateRevised": {"Year": "2021", "Month": "02", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "08", "Day": "14"}], "Language": ["eng"], "ELocationID": ["5858", "10.3390/ijms21165858"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "21", "Issue": "16", "PubDate": {"Year": "2020", "Month": "Aug", "Day": "14"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Revisiting the Amyloid Cascade Hypothesis: From Anti-A\u03b2 Therapeutics to Auspicious New Ways for Alzheimer's Disease.", "Abstract": {"AbstractText": ["Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder related to age, characterized by the cerebral deposition of fibrils, which are made from the amyloid-\u03b2 (A\u03b2), a peptide of 40-42 amino acids. The conversion of A\u03b2 into neurotoxic oligomeric, fibrillar, and protofibrillar assemblies is supposed to be the main pathological event in AD. After A\u03b2 accumulation, the clinical symptoms fall out predominantly due to the deficient brain clearance of the peptide. For several years, researchers have attempted to decline the A\u03b2 monomer, oligomer, and aggregate levels, as well as plaques, employing agents that facilitate the reduction of A\u03b2 and antagonize A\u03b2 aggregation, or raise A\u03b2 clearance from brain. Unluckily, broad clinical trials with mild to moderate AD participants have shown that these approaches were unsuccessful. Several clinical trials are running involving patients whose disease is at an early stage, but the preliminary outcomes are not clinically impressive. Many studies have been conducted against oligomers of A\u03b2 which are the utmost neurotoxic molecular species. Trials with monoclonal antibodies directed against A\u03b2 oligomers have exhibited exciting findings. Nevertheless, A\u03b2 oligomers maintain equivalent states in both monomeric and aggregation forms; so, previously administered drugs that precisely decrease A\u03b2 monomer or A\u03b2 plaques ought to have displayed valuable clinical benefits. In this article, A\u03b2-based therapeutic strategies are discussed and several promising new ways to fight against AD are appraised."]}, "AuthorList": [{"Identifier": ["0000-0002-0805-7840"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, Southeast University, Dhaka 1213, Bangladesh."}, {"Identifier": [], "Affiliation": "Pharmakon Neuroscience Research Network, Dhaka 1207, Bangladesh."}], "LastName": "Uddin", "ForeName": "Md Sahab", "Initials": "MS"}, {"Identifier": ["0000-0002-6078-8587"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh."}], "LastName": "Kabir", "ForeName": "Md Tanvir", "Initials": "MT"}, {"Identifier": ["0000-0002-1133-268X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi 6205, Bangladesh."}], "LastName": "Rahman", "ForeName": "Md Sohanur", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India."}], "LastName": "Behl", "ForeName": "Tapan", "Initials": "T"}, {"Identifier": ["0000-0003-3023-4871"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, PO Box 1039, 51687 Reims CEDEX 2, France."}], "LastName": "Jeandet", "ForeName": "Philippe", "Initials": "P"}, {"Identifier": ["0000-0002-9820-2078"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Ashraf", "ForeName": "Ghulam Md", "Initials": "GM"}, {"Identifier": ["0000-0002-1185-8884"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Quality of Vegetables and Medicinal Plants, Department of Vegetable Crops and Medicinal Plants, University of Life Sciences in Lublin, 15 Akademicka Street, 20-950 Lublin, Poland."}], "LastName": "Najda", "ForeName": "Agnieszka", "Initials": "A"}, {"Identifier": ["0000-0002-3017-9924"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11474, Saudi Arabia."}], "LastName": "Bin-Jumah", "ForeName": "May N", "Initials": "MN"}, {"Identifier": ["0000-0002-2519-6690"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China."}, {"Identifier": [], "Affiliation": "Pharmacognosy Group, Department of Pharmaceutical Biosciences, Uppsala University, SE-751 23 Uppsala, Sweden."}, {"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science, Menoufia University, Shebin El-Koom 32512, Egypt."}], "LastName": "El-Seedi", "ForeName": "Hesham R", "Initials": "HR"}, {"Identifier": ["0000-0002-4341-2713"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt."}], "LastName": "Abdel-Daim", "ForeName": "Mohamed M", "Initials": "MM"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amyloid"}, {"RegistryNumber": "0", "NameOfSubstance": "Amyloid beta-Peptides"}, {"RegistryNumber": "0", "NameOfSubstance": "Biomarkers"}, {"RegistryNumber": "0", "NameOfSubstance": "tau Proteins"}], "MeshHeadingList": [{"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["metabolism"], "DescriptorName": "Amyloid"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Amyloid beta-Peptides"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Biomarkers"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Models, Biological"}, {"QualifierName": ["metabolism"], "DescriptorName": "tau Proteins"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Koudinov A.R., Berezov T.T. Alzheimer\u2019s amyloid-beta (A beta) is an essential synaptic protein, not neurotoxic junk. Acta Neurobiol. Exp. (Wars) 2004;64:71\u201379.", "ArticleIdList": ["15190681"]}, {"Citation": "Sharma P., Sharma A., Fayaz F., Wakode S., Pottoo F.H. Biological Signatures of Alzheimer\u2019s Disease. Curr. Top. Med. Chem. 2020;20:770\u2013781. doi: 10.2174/1568026620666200228095553.", "ArticleIdList": ["10.2174/1568026620666200228095553", "32108008"]}, {"Citation": "Uddin M.S., Al Mamun A., Asaduzzaman M., Hosn F., Abu Sufian M., Takeda S., Herrera-Calderon O., Abdel-Daim M.M., Uddin G.M.S., Noor M.A.A., et al. Spectrum of Disease and Prescription Pattern for Outpatients with Neurological Disorders: An Empirical Pilot Study in Bangladesh. Ann. Neurosci. 2018;25:25\u201337. doi: 10.1159/000481812.", "ArticleIdList": ["10.1159/000481812", "PMC5981591", "29887680"]}, {"Citation": "Khorrami A., Ghanbarzadeh S., Mahmoudi J., Nayebi A.M., Maleki-Dizaji N., Garjani A. Investigation of the memory impairment in rats fed with oxidized-cholesterol-rich diet employing passive avoidance test. Drug Res. (Stuttg) 2015;65:231\u2013237. doi: 10.1055/s-0034-1370950.", "ArticleIdList": ["10.1055/s-0034-1370950", "24668576"]}, {"Citation": "Grienberger C., Rochefort N.L., Adelsberger H., Henning H.A., Hill D.N., Reichwald J., Staufenbiel M., Konnerth A. Staged decline of neuronal function in vivo in an animal model of Alzheimer\u2019s disease. Nat. Commun. 2012;3:774. doi: 10.1038/ncomms1783.", "ArticleIdList": ["10.1038/ncomms1783", "PMC3337977", "22491322"]}, {"Citation": "Qiu C., Kivipelto M., von Strauss E. Epidemiology of Alzheimer\u2019s disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 2009;11:111\u2013128.", "ArticleIdList": ["PMC3181909", "19585947"]}, {"Citation": "G\u00f6tz J., Ittner L.M. Animal models of Alzheimer\u2019s disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008;9:532\u2013544. doi: 10.1038/nrn2420.", "ArticleIdList": ["10.1038/nrn2420", "18568014"]}, {"Citation": "Nordberg A. Amyloid plaque imaging in vivo: Current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging. 2008;35:46\u201350. doi: 10.1007/s00259-007-0700-2.", "ArticleIdList": ["10.1007/s00259-007-0700-2", "18188557"]}, {"Citation": "Dubois B., Feldman H.H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734\u2013746. doi: 10.1016/S1474-4422(07)70178-3.", "ArticleIdList": ["10.1016/S1474-4422(07)70178-3", "17616482"]}, {"Citation": "Uddin M.S., Kabir M.T., Jakaria M., Sobarzo-S\u00e1nchez E., Barreto G.E., Perveen A., Hafeez A., Bin-Jumah M.N., Abdel-Daim M.M., Ashraf G.M. Exploring the potential of neuroproteomics in Alzheimer\u2019s disease. Curr. Top. Med. Chem. 2020;20 doi: 10.2174/1568026620666200603112030.", "ArticleIdList": ["10.2174/1568026620666200603112030", "32493192"]}, {"Citation": "Butterfield D.A., Boyd-Kimball D. Amyloid \u03b2-Peptide(1-42) Contributes to the Oxidative Stress and Neurodegeneration Found in Alzheimer Disease Brain. Brain Pathol. 2006;14:426\u2013432. doi: 10.1111/j.1750-3639.2004.tb00087.x.", "ArticleIdList": ["10.1111/j.1750-3639.2004.tb00087.x", "15605990"]}, {"Citation": "Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., W\u00f6lfing H., Chieng B.C., Christie M.J., Napier I.A., et al. Dendritic function of tau mediates amyloid-\u03b2 toxicity in alzheimer\u2019s disease mouse models. Cell. 2010;142:387\u2013397. doi: 10.1016/j.cell.2010.06.036.", "ArticleIdList": ["10.1016/j.cell.2010.06.036", "20655099"]}, {"Citation": "Uddin M.S., Al Mamun A., Rahman M.A., Behl T., Perveen A., Hafeez A., Bin-Jumah M.N., Abdel-Daim M.M., Ashraf G.M. Emerging proof of protein misfolding and interactions in multifactorial Alzheimer\u2019s disease. Curr. Top. Med. Chem. 2020;20 doi: 10.2174/1568026620666200601161703.", "ArticleIdList": ["10.2174/1568026620666200601161703", "32479244"]}, {"Citation": "Moreira P.I., Carvalho C., Zhu X., Smith M.A., Perry G. Mitochondrial dysfunction is a trigger of Alzheimer\u2019s disease pathophysiology. Biochim. Biophys. Acta Mol. Basis Dis. 2010;1802:2\u201310. doi: 10.1016/j.bbadis.2009.10.006.", "ArticleIdList": ["10.1016/j.bbadis.2009.10.006", "19853658"]}, {"Citation": "Kabir M.T., Uddin M.S., Mamun A.A., Jeandet P., Aleya L., Mansouri R.A., Ashraf G.M., Mathew B., Bin-Jumah M.N., Abdel-Daim M.M. Combination Drug Therapy for the Management of Alzheimer\u2019s Disease. Int. J. Mol. Sci. 2020;21:3272. doi: 10.3390/ijms21093272.", "ArticleIdList": ["10.3390/ijms21093272", "PMC7246721", "32380758"]}, {"Citation": "Kabir M.T., Uddin M.S., Begum M.M., Thangapandiyan S., Rahman M.S., Aleya L., Mathew B., Ahmed M., Ashraf G.M., Barreto G.E. Cholinesterase Inhibitors for Alzheimer\u2019s Disease: Multitargeting Strategy based on Anti-Alzheimer\u2019s Drugs Repositioning. Curr. Pharm. Des. 2019;25:3519\u20133535. doi: 10.2174/1381612825666191008103141.", "ArticleIdList": ["10.2174/1381612825666191008103141", "31593530"]}, {"Citation": "Kabir M.T., Abu Sufian M., Uddin M.S., Begum M.M., Akhter S., Islam A., Mathew B., Islam M.S., Amran M.S., Md Ashraf G. NMDA Receptor Antagonists: Repositioning of Memantine as Multitargeting Agent for Alzheimer\u2019s Therapy. Curr. Pharm. Des. 2019;25:3506\u20133518. doi: 10.2174/1381612825666191011102444.", "ArticleIdList": ["10.2174/1381612825666191011102444", "31604413"]}, {"Citation": "Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer\u2019s disease brain. A review. Free Radic. Res. 2002;36:1307\u20131313. doi: 10.1080/1071576021000049890.", "ArticleIdList": ["10.1080/1071576021000049890", "12607822"]}, {"Citation": "Rahman M.A., Rahman M.R., Zaman T., Uddin M.S., Islam R., Abdel-Daim M.M., Rhim H. Emerging Potential of Naturally Occurring Autophagy Modulator against Neurodegeneration. Curr. Pharm. Des. 2020;26:772\u2013779. doi: 10.2174/1381612826666200107142541.", "ArticleIdList": ["10.2174/1381612826666200107142541", "31914904"]}, {"Citation": "Uddin M.S., Al Mamun A., Jakaria M., Thangapandiyan S., Ahmad J., Rahman M.A., Mathew B., Abdel-Daim M.M., Aleya L. Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci. Total Environ. 2020;707:135624. doi: 10.1016/j.scitotenv.2019.135624.", "ArticleIdList": ["10.1016/j.scitotenv.2019.135624", "31784171"]}, {"Citation": "Ibrahim A.M., Pottoo F.H., Dahiya E.S., Khan F.A., Kumar J.S. Neuron-Glia interaction: Molecular basis of Alzheimer\u2019s Disease and Applications of Neuroproteomics. Eur. J. Neurosci. 2020;52:2931\u20132943. doi: 10.1111/ejn.14838.", "ArticleIdList": ["10.1111/ejn.14838", "32463535"]}, {"Citation": "Bao F., Wicklund L., Lacor P.N., Klein W.L., Nordberg A., Marutle A. Different \u03b2-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol. Aging. 2012;33:825.e1\u2013825.e13. doi: 10.1016/j.neurobiolaging.2011.05.003.", "ArticleIdList": ["10.1016/j.neurobiolaging.2011.05.003", "21683475"]}, {"Citation": "Uddin M.S., Kabir M.T., Tewari D., Al Mamun A., Mathew B., Aleya L., Barreto G.E., Bin-Jumah M.N., Abdel-Daim M.M., Ashraf G.M. Revisiting the role of brain and peripheral A\u03b2 in the pathogenesis of Alzheimer\u2019s disease. J. Neurol. Sci. 2020;416:116974. doi: 10.1016/j.jns.2020.116974.", "ArticleIdList": ["10.1016/j.jns.2020.116974", "32559516"]}, {"Citation": "Bennett R.E., DeVos S.L., Dujardin S., Corjuc B., Gor R., Gonzalez J., Roe A.D., Frosch M.P., Pitstick R., Carlson G.A., et al. Enhanced Tau Aggregation in the Presence of Amyloid \u03b2. Am. J. Pathol. 2017;187:1601\u20131612. doi: 10.1016/j.ajpath.2017.03.011.", "ArticleIdList": ["10.1016/j.ajpath.2017.03.011", "PMC5500829", "28500862"]}, {"Citation": "Vasconcelos B., Stancu I.C., Buist A., Bird M., Wang P., Vanoosthuyse A., Van Kolen K., Verheyen A., Kienlen-Campard P., Octave J.N., et al. Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. Acta Neuropathol. 2016;131:549\u2013569. doi: 10.1007/s00401-015-1525-x.", "ArticleIdList": ["10.1007/s00401-015-1525-x", "PMC4789256", "26739002"]}, {"Citation": "G\u00f6tz J., Chen F., Van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A\u03b242 fibrils. Science. 2001;293:1491\u20131495. doi: 10.1126/science.1062097.", "ArticleIdList": ["10.1126/science.1062097", "11520988"]}, {"Citation": "Bolmont T., Clavaguera F., Meyer-Luehmann M., Herzig M.C., Radde R., Staufenbiel M., Lewis J., Hutton M., Tolnay M., Jucker M. Induction of tau pathology by intracerebral infusion of amyloid-\u03b2-containing brain extract and by amyloid-\u03b2 deposition in APP x tau transgenic mice. Am. J. Pathol. 2007;171:2012\u20132020. doi: 10.2353/ajpath.2007.070403.", "ArticleIdList": ["10.2353/ajpath.2007.070403", "PMC2111123", "18055549"]}, {"Citation": "Pooler A.M., Polydoro M., Maury E.A., Nicholls S.B., Reddy S.M., Wegmann S., William C., Saqran L., Cagsal-Getkin O., Pitstick R., et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer\u2019s disease. Acta Neuropathol. Commun. 2015;3:14. doi: 10.1186/s40478-015-0199-x.", "ArticleIdList": ["10.1186/s40478-015-0199-x", "PMC4371800", "25853174"]}, {"Citation": "Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487\u20131491. doi: 10.1126/science.1058189.", "ArticleIdList": ["10.1126/science.1058189", "11520987"]}, {"Citation": "He Z., Guo J.L., McBride J.D., Narasimhan S., Kim H., Changolkar L., Zhang B., Gathagan R.J., Yue C., Dengler C., et al. Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 2018;24:29\u201338. doi: 10.1038/nm.4443.", "ArticleIdList": ["10.1038/nm.4443", "PMC5760353", "29200205"]}, {"Citation": "Zetterberg H., Blennow K., Hanse E. Amyloid \u03b2 and APP as biomarkers for Alzheimer\u2019s disease. Exp. Gerontol. 2010;45:23\u201329. doi: 10.1016/j.exger.2009.08.002.", "ArticleIdList": ["10.1016/j.exger.2009.08.002", "19698775"]}, {"Citation": "Stefani A., Bernardini S., Panella M., Pierantozzi M., Nuccetelli M., Koch G., Urbani A., Giordano A., Martorana A., Orlacchio A., et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J. Neurol. Sci. 2005;237:83\u201388. doi: 10.1016/j.jns.2005.05.016.", "ArticleIdList": ["10.1016/j.jns.2005.05.016", "15990115"]}, {"Citation": "Noguchi M., Yoshita M., Matsumoto Y., Ono K., Iwasa K., Yamada M. Decreased \u03b2-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 2005;237:61\u201365. doi: 10.1016/j.jns.2005.05.015.", "ArticleIdList": ["10.1016/j.jns.2005.05.015", "15992827"]}, {"Citation": "Cedazo-Minguez A., Winblad B. Biomarkers for Alzheimer\u2019s disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp. Gerontol. 2010;45:5\u201314. doi: 10.1016/j.exger.2009.09.008.", "ArticleIdList": ["10.1016/j.exger.2009.09.008", "19796673"]}, {"Citation": "Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., et al. Cerebrospinal fluid \u03b2-amyloid 1-42 and tau in control subjects at risk for Alzheimer\u2019s disease: The effect of APOE \u03b54 allele. Biol. Psychiatry. 2004;56:670\u2013676. doi: 10.1016/j.biopsych.2004.07.021.", "ArticleIdList": ["10.1016/j.biopsych.2004.07.021", "15522251"]}, {"Citation": "Schoonenboom N.S., Mulder C., Van Kamp G.J., Mehta S.P., Scheltens P., Blankenstein M.A., Mehta P.D. Amyloid \u03b2 38, 40, and 42 species in cerebrospinal fluid: More of the same? Ann. Neurol. 2005;58:139\u2013142. doi: 10.1002/ana.20508.", "ArticleIdList": ["10.1002/ana.20508", "15984010"]}, {"Citation": "Xiao Z., Prieto D., Conrads T.P., Veenstra T.D., Issaq H.J. Proteomic patterns: Their potential for disease diagnosis. Mol. Cell. Endocrinol. 2005;230:95\u2013106. doi: 10.1016/j.mce.2004.10.010.", "ArticleIdList": ["10.1016/j.mce.2004.10.010", "15664456"]}, {"Citation": "Bloom G.S. Amyloid-\u03b2 and Tau. JAMA Neurol. 2014;71:505. doi: 10.1001/jamaneurol.2013.5847.", "ArticleIdList": ["10.1001/jamaneurol.2013.5847", "24493463"]}, {"Citation": "Al Mamun A., Uddin M.S., Kabir M.T., Khanum S., Sarwar M.S., Mathew B., Rauf A., Ahmed M., Ashraf G.M. Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer\u2019s Disease. Neurotox. Res. 2020;38:8\u201317. doi: 10.1007/s12640-020-00185-1.", "ArticleIdList": ["10.1007/s12640-020-00185-1", "32157628"]}, {"Citation": "Sj\u00f6gren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkels\u00f8 C., Skoog I., Wallin A., Wahlund L.O., Marcusson J., et al. Tau and Abeta42 in Cerebrospinal Fluid From Healthy Adults 21\u201393 Years of Age: Establishment of Reference Values. Clin. Chem. 2001;47:1776\u20131781.", "ArticleIdList": ["11568086"]}, {"Citation": "Blennow K. CSF biomarkers for mild cognitive impairment. J. Intern. Med. 2004;256:224\u2013234. doi: 10.1111/j.1365-2796.2004.01368.x.", "ArticleIdList": ["10.1111/j.1365-2796.2004.01368.x", "15324365"]}, {"Citation": "Blennow K. CSF biomarkers for Alzheimer\u2019s disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev. Mol. Diagn. 2005;5:661\u2013672. doi: 10.1586/14737159.5.5.661.", "ArticleIdList": ["10.1586/14737159.5.5.661", "16149870"]}, {"Citation": "Mo J.-A., Lim J.-H., Sul A.-R., Lee M., Youn Y.C., Kim H.-J. Cerebrospinal Fluid \u03b2-Amyloid1\u201342 Levels in the Differential Diagnosis of Alzheimer\u2019s Disease\u2014Systematic Review and Meta-Analysis. PLoS ONE. 2015;10:e0116802. doi: 10.1371/journal.pone.0116802.", "ArticleIdList": ["10.1371/journal.pone.0116802", "PMC4339391", "25710596"]}, {"Citation": "Hu W.T., Watts K.D., Shaw L.M., Howell J.C., Trojanowski J.Q., Basra S., Glass J.D., Lah J.J., Levey A.I. CSF beta-amyloid 1-42\u2014what are we measuring in Alzheimer\u2019s disease? Ann. Clin. Transl. Neurol. 2015;2:131\u2013139. doi: 10.1002/acn3.160.", "ArticleIdList": ["10.1002/acn3.160", "PMC4338954", "25750918"]}, {"Citation": "Quiroz Y.T., Sperling R.A., Norton D.J., Baena A., Arboleda-Velasquez J.F., Cosio D., Schultz A., Lapoint M., Guzman-Velez E., Miller J.B., et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 2018;75:548\u2013556. doi: 10.1001/jamaneurol.2017.4907.", "ArticleIdList": ["10.1001/jamaneurol.2017.4907", "PMC5885174", "29435558"]}, {"Citation": "Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M.L., Volpe S., Ratto S., Dagna-Bricarelli F., et al. Plasma levels of amyloid \u03b2-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63:828\u2013831. doi: 10.1212/01.WNL.0000137040.64252.ED.", "ArticleIdList": ["10.1212/01.WNL.0000137040.64252.ED", "15365131"]}, {"Citation": "Borroni B., Di Luca M., Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? Eur. J. Pharmacol. 2006;545:73\u201380. doi: 10.1016/j.ejphar.2006.06.023.", "ArticleIdList": ["10.1016/j.ejphar.2006.06.023", "16831417"]}, {"Citation": "Brettschneider S., Morgenthaler N.G., Teipel S.J., Fischer-Schulz C., B\u00fcrger K., Dodel R., Du Y., M\u00f6ller H.J., Bergmann A., Hampel H. Decreased serum amyloid \u03b21-42 autoantibody levels in Alzheimer\u2019s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid \u03b21-42 peptide. Biol. Psychiatry. 2005;57:813\u2013816. doi: 10.1016/j.biopsych.2004.12.008.", "ArticleIdList": ["10.1016/j.biopsych.2004.12.008", "15820240"]}, {"Citation": "Gustaw-Rothenberg K.A., Siedlak S.L., Bonda D.J., Lerner A., Tabaton M., Perry G., Smith M.A. Dissociated amyloid-\u03b2 antibody levels as a serum biomarker for the progression of Alzheimer\u2019s disease: A population-based study. Exp. Gerontol. 2010;45:47\u201352. doi: 10.1016/j.exger.2009.10.003.", "ArticleIdList": ["10.1016/j.exger.2009.10.003", "PMC2815174", "19819324"]}, {"Citation": "Uddin M.S., Kabir M.T., Jeandet P., Mathew B., Ashraf G.M., Perveen A., Bin-Jumah M.N., Mousa S.A., Abdel-Daim M.M. Novel Anti-Alzheimer\u2019s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. Oxid. Med. Cell. Longev. 2020;2020:1\u201319. doi: 10.1155/2020/7039138.", "ArticleIdList": ["10.1155/2020/7039138", "PMC7206886", "32411333"]}, {"Citation": "Weggen S., Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 2012;4:1\u201314. doi: 10.1186/alzrt107.", "ArticleIdList": ["10.1186/alzrt107", "PMC3334542", "22494386"]}, {"Citation": "MacLeod R., Hillert E.-K., Cameron R.T., Baillie G.S. The role and therapeutic targeting of \u03b1-, \u03b2- and \u03b3-secretase in Alzheimer\u2019s disease. Futur. Sci. OA. 2015;1:FSO11. doi: 10.4155/fso.15.9.", "ArticleIdList": ["10.4155/fso.15.9", "PMC5137966", "28031886"]}, {"Citation": "Citron M., Teplow D.B., Selkoe D.J. Generation of amyloid \u03b2 protein from its precursor is sequence specific. Neuron. 1995;14:661\u2013670. doi: 10.1016/0896-6273(95)90323-2.", "ArticleIdList": ["10.1016/0896-6273(95)90323-2", "7695913"]}, {"Citation": "Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the \u03b2-amyloid precursor protein in familial Alzheimer\u2019s disease increases \u03b2-protein production. Nature. 1992;360:672\u2013674. doi: 10.1038/360672a0.", "ArticleIdList": ["10.1038/360672a0", "1465129"]}, {"Citation": "Uddin M.S., Kabir M.T., Rahman M.M., Mathew B., Shah M.A., Ashraf G.M. TV 3326 for Alzheimer\u2019s dementia: A novel multimodal ChE and MAO inhibitors to mitigate Alzheimer\u2019s-like neuropathology. J. Pharm. Pharmacol. 2020;72:1001\u20131012. doi: 10.1111/jphp.13244.", "ArticleIdList": ["10.1111/jphp.13244", "32149402"]}, {"Citation": "Beyreuther K., Masters C.L. Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer\u2019s disease: Precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1991;1:241\u2013251. doi: 10.1111/j.1750-3639.1991.tb00667.x.", "ArticleIdList": ["10.1111/j.1750-3639.1991.tb00667.x", "1669714"]}, {"Citation": "Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol. Sci. 1991;12:383\u2013388. doi: 10.1016/0165-6147(91)90609-V.", "ArticleIdList": ["10.1016/0165-6147(91)90609-V", "1763432"]}, {"Citation": "Selkoe D.J. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u2013498. doi: 10.1016/0896-6273(91)90052-2.", "ArticleIdList": ["10.1016/0896-6273(91)90052-2", "1673054"]}, {"Citation": "Hardy J.A., Higgins G.A. Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science. 1992;256:184\u2013185. doi: 10.1126/science.1566067.", "ArticleIdList": ["10.1126/science.1566067", "1566067"]}, {"Citation": "Kabir M.T., Uddin M.S., Setu J.R., Ashraf G.M., Bin-Jumah M.N., Abdel-Daim M.M. Exploring the Role of PSEN mutations in the pathogenesis of Alzheimer\u2019s disease. Neurotox. Res. 2020 doi: 10.1007/s12640-020-00232-x.", "ArticleIdList": ["10.1007/s12640-020-00232-x", "32556937"]}, {"Citation": "Karran E., Mercken M., Strooper B. De The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011;10:698\u2013712. doi: 10.1038/nrd3505.", "ArticleIdList": ["10.1038/nrd3505", "21852788"]}, {"Citation": "Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., et al. Familial Alzheimer\u2019s disease-linked presenilin I variants elevate a\u03b21-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005\u20131013. doi: 10.1016/S0896-6273(00)80230-5.", "ArticleIdList": ["10.1016/S0896-6273(00)80230-5", "8938131"]}, {"Citation": "Ertekin-Taner N. Genetics of Alzheimer\u2019s Disease: A Centennial Review. Neurol. Clin. 2007;25:611\u2013667. doi: 10.1016/j.ncl.2007.03.009.", "ArticleIdList": ["10.1016/j.ncl.2007.03.009", "PMC2735049", "17659183"]}, {"Citation": "Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., J\u00e4ggi F., Wolburg H., Gengler S., et al. A\u03b242-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940\u2013946. doi: 10.1038/sj.embor.7400784.", "ArticleIdList": ["10.1038/sj.embor.7400784", "PMC1559665", "16906128"]}, {"Citation": "Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., Beach T., Sue L., Wong P., Price D., et al. Elevated \u03b2-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 2003;9:3\u20134. doi: 10.1038/nm0103-3.", "ArticleIdList": ["10.1038/nm0103-3", "12514700"]}, {"Citation": "Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease. Science. 2010;330:1774. doi: 10.1126/science.1197623.", "ArticleIdList": ["10.1126/science.1197623", "PMC3073454", "21148344"]}, {"Citation": "Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837\u20131844. doi: 10.1212/01.wnl.0000219668.47116.e6.", "ArticleIdList": ["10.1212/01.wnl.0000219668.47116.e6", "16801647"]}, {"Citation": "Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R.J., Visser P.J., Aalten P., Aarsland D., Alcolea D., et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA J. Am. Med. Assoc. 2015;313:1924\u20131938. doi: 10.1001/jama.2015.4668.", "ArticleIdList": ["10.1001/jama.2015.4668", "PMC4486209", "25988462"]}, {"Citation": "Vos S.J.B., Xiong C., Visser P.J., Jasielec M.S., Hassenstab J., Grant E.A., Cairns N.J., Morris J.C., Holtzman D.M., Fagan A.M. Preclinical Alzheimer\u2019s disease and its outcome: A longitudinal cohort study. Lancet Neurol. 2013;12:957\u2013965. doi: 10.1016/S1474-4422(13)70194-7.", "ArticleIdList": ["10.1016/S1474-4422(13)70194-7", "PMC3904678", "24012374"]}, {"Citation": "Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study. Lancet Neurol. 2013;12:357\u2013367. doi: 10.1016/S1474-4422(13)70044-9.", "ArticleIdList": ["10.1016/S1474-4422(13)70044-9", "23477989"]}, {"Citation": "Burnham S.C., Bourgeat P., Dor\u00e9 V., Savage G., Brown B., Laws S., Maruff P., Salvado O., Ames D., Martins R.N., et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer\u2019s disease pathophysiology (SNAP) or Alzheimer\u2019s disease pathology: A longitudinal study. Lancet Neurol. 2016;15:1044\u20131053. doi: 10.1016/S1474-4422(16)30125-9.", "ArticleIdList": ["10.1016/S1474-4422(16)30125-9", "27450471"]}, {"Citation": "Petersen R.C., Wiste H.J., Weigand S.D., Rocca W.A., Roberts R.O., Mielke M.M., Lowe V.J., Knopman D.S., Pankratz V.S., Machulda M.M., et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73:85\u201392. doi: 10.1001/jamaneurol.2015.3098.", "ArticleIdList": ["10.1001/jamaneurol.2015.3098", "PMC4710552", "26595683"]}, {"Citation": "Donohue M.C., Sperling R.A., Petersen R., Sun C.K., Weiner M., Aisen P.S. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA J. Am. Med. Assoc. 2017;317:2305\u20132316. doi: 10.1001/jama.2017.6669.", "ArticleIdList": ["10.1001/jama.2017.6669", "PMC5736301", "28609533"]}, {"Citation": "Lauritzen I., Pardossi-Piquard R., Bauer C., Brigham E., Abraham J.D., Ranaldi S., Fraser P., St-George-Hyslop P., Le Thuc O., Espin V., et al. The \u03b2-secretase-derived C-terminal fragment of \u03b2APP, C99, but not A\u03b2, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 2012;32:16243\u201316255. doi: 10.1523/JNEUROSCI.2775-12.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.2775-12.2012", "PMC5019353", "23152608"]}, {"Citation": "Lauritzen I., Pardossi-Piquard R., Bourgeois A., Pagnotta S., Biferi M.G., Barkats M., Lacor P., Klein W., Bauer C., Checler F. Intraneuronal aggregation of the \u03b2-CTF fragment of APP (C99) induces A\u03b2-independent lysosomal-autophagic pathology. Acta Neuropathol. 2016;132:257\u2013276. doi: 10.1007/s00401-016-1577-6.", "ArticleIdList": ["10.1007/s00401-016-1577-6", "PMC4947121", "27138984"]}, {"Citation": "Pasternak S.H., Callahan J.W., Mahuran D.J. The role of the endosomal/lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer\u2019s disease: Reexamining the spatial paradox from a lysosomal perspective. J. Alzheimer\u2019s Dis. 2004;6:53\u201365. doi: 10.3233/JAD-2004-6107.", "ArticleIdList": ["10.3233/JAD-2004-6107", "15004328"]}, {"Citation": "Schubert D., Behl C. The expression of amyloid beta protein precursor protects nerve cells from \u03b2-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix. Brain Res. 1993;629:275\u2013282. doi: 10.1016/0006-8993(93)91331-L.", "ArticleIdList": ["10.1016/0006-8993(93)91331-L", "7906601"]}, {"Citation": "Furukawa K., Mattson M.P. Secreted amyloid precursor protein a selectively suppresses N-methyl-D- aspartate currents in hippocampal neurons: Involvement of cyclic GMP. Neuroscience. 1998;83:429\u2013438. doi: 10.1016/S0306-4522(97)00398-9.", "ArticleIdList": ["10.1016/S0306-4522(97)00398-9", "9460751"]}, {"Citation": "Bell K.F.S., Zheng L., Fahrenholz F., Cuello A.C. ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol. Aging. 2008;29:554\u2013565. doi: 10.1016/j.neurobiolaging.2006.11.004.", "ArticleIdList": ["10.1016/j.neurobiolaging.2006.11.004", "17187903"]}, {"Citation": "Mattson M.P. Cellular actions of \u03b2-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 1997;77:1081\u20131132. doi: 10.1152/physrev.1997.77.4.1081.", "ArticleIdList": ["10.1152/physrev.1997.77.4.1081", "9354812"]}, {"Citation": "Caill\u00e9 I., Allinquant B., Dupont E., Bouillot C., Langer A., M\u00fcller U., Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development. 2004;131:2173\u20132181. doi: 10.1242/dev.01103.", "ArticleIdList": ["10.1242/dev.01103", "15073156"]}, {"Citation": "Obregon D., Hou H., Deng J., Giunta B., Tian J., Darlington D., Shahaduzzaman M., Zhu Y., Mori T., Mattson M.P., et al. Soluble amyloid precursor protein-\u03b1 modulates \u03b2-secretase activity and amyloid-\u03b2 2 generation. Nat. Commun. 2012;3:777. doi: 10.1038/ncomms1781.", "ArticleIdList": ["10.1038/ncomms1781", "PMC3520614", "22491325"]}, {"Citation": "Peters-Libeu C., Campagna J., Mitsumori M., Poksay K.S., Spilman P., Sabogal A., Bredesen D.E., John V. SA\u03b2PP\u03b1 is a Potent Endogenous Inhibitor of BACE1. J. Alzheimer\u2019s Dis. 2015;47:545\u2013555. doi: 10.3233/JAD-150282.", "ArticleIdList": ["10.3233/JAD-150282", "26401691"]}, {"Citation": "Deng J., Habib A., Obregon D.F., Barger S.W., Giunta B., Wang Y.J., Hou H., Sawmiller D., Tan J. Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3\u03b2 signaling pathway. J. Neurochem. 2015;135:630\u2013637. doi: 10.1111/jnc.13351.", "ArticleIdList": ["10.1111/jnc.13351", "PMC4624213", "26342176"]}, {"Citation": "Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology. 1992;42:631\u2013639. doi: 10.1212/WNL.42.3.631.", "ArticleIdList": ["10.1212/WNL.42.3.631", "1549228"]}, {"Citation": "Bierer L.M., Hof P.R., Purohit D.P., Carlin L., Schmeidler J., Davis K.L., Perl D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer\u2019s disease. Arch. Neurol. 1995;52:81\u201388. doi: 10.1001/archneur.1995.00540250089017.", "ArticleIdList": ["10.1001/archneur.1995.00540250089017", "7826280"]}, {"Citation": "Mamun A.A., Uddin M.S., Mathew B., Ashraf G.M. Toxic Tau: Structural Origins of Tau Aggregation in Alzheimer\u2019s Disease. Neural Regen. Res. 2020;15:1417\u20131420.", "ArticleIdList": ["PMC7059584", "31997800"]}, {"Citation": "G\u00f3mez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease. Ann. Neurol. 1997;41:17\u201324. doi: 10.1002/ana.410410106.", "ArticleIdList": ["10.1002/ana.410410106", "9005861"]}, {"Citation": "Kabir M.T., Uddin M.S., Abdeen A., Ashraf G.M., Perveen A., Hafeez A., Bin-Jumah M.N., Abdel-Daim M.M. Evidence linking protein misfolding to quality control in progressive neurodegenerative diseases. Curr. Top. Med. Chem. 2020;20 doi: 10.2174/1568026620666200618114924.", "ArticleIdList": ["10.2174/1568026620666200618114924", "32552649"]}, {"Citation": "Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., Arnold S.E. Neurofibrillary Tangles Mediate the Association of Amyloid Load with Clinical Alzheimer Disease and Level of Cognitive Function. Arch. Neurol. 2004;61:378\u2013384. doi: 10.1001/archneur.61.3.378.", "ArticleIdList": ["10.1001/archneur.61.3.378", "15023815"]}, {"Citation": "Wang L., Benzinger T.L., Su Y., Christensen J., Friedrichsen K., Aldea P., McConathy J., Cairns N.J., Fagan A.M., Morris J.C., et al. Evaluation of Tau imaging in staging Alzheimer disease and revealing interactions between \u03b2-Amyloid and tauopathy. JAMA Neurol. 2016;73:1070\u20131077. doi: 10.1001/jamaneurol.2016.2078.", "ArticleIdList": ["10.1001/jamaneurol.2016.2078", "PMC5237382", "27454922"]}, {"Citation": "Sutphen C.L., McCue L., Herries E.M., Xiong C., Ladenson J.H., Holtzman D.M., Fagan A.M. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:869\u2013879. doi: 10.1016/j.jalz.2018.01.012.", "ArticleIdList": ["10.1016/j.jalz.2018.01.012", "PMC6110083", "29580670"]}, {"Citation": "McDade E., Wang G., Gordon B.A., Hassenstab J., Benzinger T.L.S., Buckles V., Fagan A.M., Holtzman D.M., Cairns N.J., Goate A.M., et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91:E1295\u2013E1306. doi: 10.1212/WNL.0000000000006277.", "ArticleIdList": ["10.1212/WNL.0000000000006277", "PMC6177272", "30217935"]}, {"Citation": "Sato C., Barth\u00e9lemy N.R., Mawuenyega K.G., Patterson B.W., Gordon B.A., Jockel-Balsarotti J., Sullivan M., Crisp M.J., Kasten T., Kirmess K.M., et al. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97:1284\u20131298. doi: 10.1016/j.neuron.2018.02.015.", "ArticleIdList": ["10.1016/j.neuron.2018.02.015", "PMC6137722", "29566794"]}, {"Citation": "Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006;5:228\u2013234. doi: 10.1016/S1474-4422(06)70355-6.", "ArticleIdList": ["10.1016/S1474-4422(06)70355-6", "16488378"]}, {"Citation": "Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u2013259. doi: 10.1007/BF00308809.", "ArticleIdList": ["10.1007/BF00308809", "1759558"]}, {"Citation": "Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389\u2013404. doi: 10.1007/s00401-006-0127-z.", "ArticleIdList": ["10.1007/s00401-006-0127-z", "PMC3906709", "16906426"]}, {"Citation": "Thal D.R., R\u00fcb U., Orantes M., Braak H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u20131800. doi: 10.1212/WNL.58.12.1791.", "ArticleIdList": ["10.1212/WNL.58.12.1791", "12084879"]}, {"Citation": "Davidson Y.S., Robinson A., Prasher V.P., Mann D.M.A. The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer\u2019s disease in individuals with Down syndrome. Acta Neuropathol. Commun. 2018;6:56. doi: 10.1186/s40478-018-0559-4.", "ArticleIdList": ["10.1186/s40478-018-0559-4", "PMC6030772", "29973279"]}, {"Citation": "Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 1998;111:3167\u20133177.", "ArticleIdList": ["9763511"]}, {"Citation": "Nakazawa T., Komai S., Tezuka T., Hisatsune C., Umemori H., Semba K., Mishina M., Manabe T., Yamamoto T. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR\u03b52 (NR2B) subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 2001;276:693\u2013699. doi: 10.1074/jbc.M008085200.", "ArticleIdList": ["10.1074/jbc.M008085200", "11024032"]}, {"Citation": "Rong Y., Lu X., Bernard A., Khrestchatisky M., Baudry M. Tyrosine phosphorylation of ionotropic glutamate receptors by Fyn or Src differentially modulates their susceptibility to calpain and enhances their binding to spectrin and PSD-95. J. Neurochem. 2001;79:382\u2013390. doi: 10.1046/j.1471-4159.2001.00565.x.", "ArticleIdList": ["10.1046/j.1471-4159.2001.00565.x", "11677266"]}, {"Citation": "Tezuka T., Umemori H., Akiyama T., Nakanishi S., Yamamoto T. PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc. Natl. Acad. Sci. USA. 1999;96:435\u2013440. doi: 10.1073/pnas.96.2.435.", "ArticleIdList": ["10.1073/pnas.96.2.435", "PMC15154", "9892651"]}, {"Citation": "Salter M.W., Kalia L.V. SRC kinases: A hub for NMDA receptor regulation. Nat. Rev. Neurosci. 2004;5:317\u2013328. doi: 10.1038/nrn1368.", "ArticleIdList": ["10.1038/nrn1368", "15034556"]}, {"Citation": "Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., Wang Y.T., Salter M.W., Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 2002;298:846\u2013850. doi: 10.1126/science.1072873.", "ArticleIdList": ["10.1126/science.1072873", "12399596"]}, {"Citation": "Chin J., Palop J.J., Puoliv\u00e4li J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer\u2019s disease. J. Neurosci. 2005;25:9694\u20139703. doi: 10.1523/JNEUROSCI.2980-05.2005.", "ArticleIdList": ["10.1523/JNEUROSCI.2980-05.2005", "PMC6725734", "16237174"]}, {"Citation": "Chin J., Palop J.J., Yu G.Q., Kojima N., Masliah E., Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 2004;24:4692\u20134697. doi: 10.1523/JNEUROSCI.0277-04.2004.", "ArticleIdList": ["10.1523/JNEUROSCI.0277-04.2004", "PMC6729387", "15140940"]}, {"Citation": "Kim H.-S., Kim E.-M., Lee J.-P., Park C.H., Kim S., Seo J.-H., Chang K.-A., Yu E., Jeong S.-J., Chong Y.H., et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3\u03b2 expression. FASEB J. 2003;17:1\u201328. doi: 10.1096/fj.03-0106fje.", "ArticleIdList": ["10.1096/fj.03-0106fje", "12923068"]}, {"Citation": "Kuhn P.-H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Ro\u00dfner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive \u03b1-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010;29:3020\u20133032. doi: 10.1038/emboj.2010.167.", "ArticleIdList": ["10.1038/emboj.2010.167", "PMC2944055", "20676056"]}, {"Citation": "De Strooper B., Vassar R., Golde T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010;6:99\u2013107. doi: 10.1038/nrneurol.2009.218.", "ArticleIdList": ["10.1038/nrneurol.2009.218", "PMC2879045", "20139999"]}, {"Citation": "Bandyopadhyay S., Goldstein L., Lahiri D., Rogers J. Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting \u03b1-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease. Curr. Med. Chem. 2007;14:2848\u20132864. doi: 10.2174/092986707782360060.", "ArticleIdList": ["10.2174/092986707782360060", "18045131"]}, {"Citation": "Hong-Qi Y., Zhi-Kun S., Sheng-Di C. Current advances in the treatment of Alzheimer\u2019s disease: Focused on considerations targeting A\u03b2 and tau. Transl. Neurodegener. 2012;1:21. doi: 10.1186/2047-9158-1-21.", "ArticleIdList": ["10.1186/2047-9158-1-21", "PMC3514124", "23210837"]}, {"Citation": "Yang H.Q., Sun Z.K., Ba M.W., Xu J., Xing Y. Involvement of protein trafficking in deprenyl-induced \u03b1-secretase activity regulation in PC12 cells. Eur. J. Pharmacol. 2009;610:37\u201341. doi: 10.1016/j.ejphar.2009.03.047.", "ArticleIdList": ["10.1016/j.ejphar.2009.03.047", "19324034"]}, {"Citation": "Filip V., Kolib\u00e1s E. Selegiline in the treatment of Alzheimer\u2019s disease: A long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J. Psychiatry Neurosci. 1999;24:234\u2013243.", "ArticleIdList": ["PMC1189014", "10354658"]}, {"Citation": "Zamrini E., McGwin G., Roseman J.M. Association between Statin Use and Alzheimer\u2019s Disease. Neuroepidemiology. 2004;23:94\u201398. doi: 10.1159/000073981.", "ArticleIdList": ["10.1159/000073981", "14739574"]}, {"Citation": "Parvathy S., Ehrlich M., Pedrini S., Diaz N., Refolo L., Buxbaum J.D., Bogush A., Petanceska S., Gandy S. Atorvastatin-induced activation of Alzheimer\u2019s alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J. Neurochem. 2004;90:1005\u20131010. doi: 10.1111/j.1471-4159.2004.02521.x.", "ArticleIdList": ["10.1111/j.1471-4159.2004.02521.x", "15287907"]}, {"Citation": "Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., Schwam E., Schindler R., Hey-Hadavi J., Demicco D.A., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956\u2013964. doi: 10.1212/WNL.0b013e3181d6476a.", "ArticleIdList": ["10.1212/WNL.0b013e3181d6476a", "20200346"]}, {"Citation": "Vellas B., Sol O., Snyder P.J., Ousset P.-J., Haddad R., Maurin M., Lemarie J.-C., Desire L., Pando M.P. EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study. Curr. Alzheimer Res. 2012;8:203\u2013212. doi: 10.2174/156720511795256053.", "ArticleIdList": ["10.2174/156720511795256053", "21222604"]}, {"Citation": "Marcade M., Bourdin J., Loiseau N., Peillon H., Rayer A., Drouin D., Schweighoffer F., D\u00e9sir\u00e9 L. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 2008;106:392\u2013404. doi: 10.1111/j.1471-4159.2008.05396.x.", "ArticleIdList": ["10.1111/j.1471-4159.2008.05396.x", "18397369"]}, {"Citation": "ClinicalTrials.gov  Study of PRX-03140 Monotherapy in Subjects with Alzheimer\u2019s Sisease.  [(accessed on 18 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00693004."}, {"Citation": "Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., Ehrhart J., Townsend K., Zeng J., Morgan D., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 2005;25:8807\u20138814. doi: 10.1523/JNEUROSCI.1521-05.2005.", "ArticleIdList": ["10.1523/JNEUROSCI.1521-05.2005", "PMC6725500", "16177050"]}, {"Citation": "Obregon D.F., Rezai-Zadeh K., Bai Y., Sun N., Hou H., Ehrhart J., Zeng J., Mori T., Arendash G.W., Shytle D., et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced \u03b1-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 2006;281:16419\u201316427. doi: 10.1074/jbc.M600617200.", "ArticleIdList": ["10.1074/jbc.M600617200", "16624814"]}, {"Citation": "ClinicalTrials.gov  Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer\u2019s Disease.  [(accessed on 18 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00951834."}, {"Citation": "Farlow M.R., Thompson R.E., Wei L.J., Tuchman A.J., Grenier E., Crockford D., Wilke S., Benison J., Alkon D.L., Moreira P. A randomized, double-blind, placebo-controlled, phase II study assessing safety, tolerability, and efficacy of bryostatin in the treatment of moderately severe to severe Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 2019;67:555\u2013570. doi: 10.3233/JAD-180759.", "ArticleIdList": ["10.3233/JAD-180759", "PMC6398557", "30530975"]}, {"Citation": "Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., et al. Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735\u2013741. doi: 10.1126/science.286.5440.735.", "ArticleIdList": ["10.1126/science.286.5440.735", "10531052"]}, {"Citation": "Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., Brashler J.R., Stratman N.C., Mathews W.R., Buhl A.E., et al. Membrane-anchored aspartyl protease with Alzheimer\u2019s disease \u03b2-secretase activity. Nature. 1999;402:533\u2013537. doi: 10.1038/990107.", "ArticleIdList": ["10.1038/990107", "10591213"]}, {"Citation": "Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer\u2019s disease therapeutics. Hum. Mol. Genet. 2001;10:1317\u20131324. doi: 10.1093/hmg/10.12.1317.", "ArticleIdList": ["10.1093/hmg/10.12.1317", "11406613"]}, {"Citation": "Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., et al. Mice deficient in BACE1, the Alzheimer\u2019s \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation. Nat. Neurosci. 2001;4:231\u2013232. doi: 10.1038/85059.", "ArticleIdList": ["10.1038/85059", "11224535"]}, {"Citation": "Ohno M., Chang L., Tseng W., Oakley H., Citron M., Klein W.L., Vassar R., Disterhoft J.F. Temporal memory deficits in Alzheimer\u2019s mouse models: Rescue by genetic deletion of BACE1. Eur. J. Neurosci. 2006;23:251\u2013260. doi: 10.1111/j.1460-9568.2005.04551.x.", "ArticleIdList": ["10.1111/j.1460-9568.2005.04551.x", "16420434"]}, {"Citation": "Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., Disterhoft J.F. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer\u2019s Disease. Neuron. 2004;41:27\u201333. doi: 10.1016/S0896-6273(03)00810-9.", "ArticleIdList": ["10.1016/S0896-6273(03)00810-9", "14715132"]}, {"Citation": "Landreth G., Jiang Q., Mandrekar S., Heneka M. PPAR\u03b3 agonists as therapeutics for the treatment of Alzheimer\u2019s disease. Neurotherapeutics. 2008;5:481\u2013489. doi: 10.1016/j.nurt.2008.05.003.", "ArticleIdList": ["10.1016/j.nurt.2008.05.003", "PMC2593876", "18625459"]}, {"Citation": "Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia. Arch. Neurol. 2009;66:300\u2013305. doi: 10.1001/archneurol.2009.27.", "ArticleIdList": ["10.1001/archneurol.2009.27", "PMC2717716", "19273747"]}, {"Citation": "ClinicalTrials.gov  Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer\u2019s disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset.  [(accessed on 18 June 2020)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT01931566."}, {"Citation": "Harrington C., Sawchak S., Chiang C., Davies J., Donovan C., Saunders A.M., Irizarry M., Jeter B., Zvartau-Hind M., van Dyck C.H., et al. Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies. Curr. Alzheimer Res. 2011;8:592\u2013606. doi: 10.2174/156720511796391935.", "ArticleIdList": ["10.2174/156720511796391935", "21592048"]}, {"Citation": "Tang J.J.N. Beta-secretase as target for amyloid-reduction therapy. Alzheimer\u2019s Dement. 2009;5:74. doi: 10.1016/j.jalz.2009.05.177.", "ArticleIdList": ["10.1016/j.jalz.2009.05.177"]}, {"Citation": "Chang W.-P., Koelsch G., Wong S., Downs D., Da H., Weerasena V., Gordon B., Devasamudram T., Bilcer G., Ghosh A.K., et al. In vivo inhibition of A\u03b2 production by memapsin 2 (\u03b2-secretase) inhibitors. J. Neurochem. 2004;89:1409\u20131416. doi: 10.1111/j.1471-4159.2004.02452.x.", "ArticleIdList": ["10.1111/j.1471-4159.2004.02452.x", "15189343"]}, {"Citation": "Ghosh A.K., Kumaragurubaran N., Hong L., Koelsh G., Tang J. Memapsin 2 (beta-secretase) inhibitors: Drug development. Curr. Alzheimer Res. 2008;5:121\u2013131. doi: 10.2174/156720508783954730.", "ArticleIdList": ["10.2174/156720508783954730", "18393797"]}, {"Citation": "Alzforum  Keystone Drug News: CoMentis BACE Inhibitor Debuts.  [(accessed on 3 August 2020)]; Available online:  https://www.alzforum.org/news/conference-coverage/keystone-drug-news-comentis-bace-inhibitor-debuts."}, {"Citation": "Ghosh A.K., Brindisi M., Tang J. Developing \u03b2-secretase inhibitors for treatment of Alzheimer\u2019s disease. J. Neurochem. 2012;120:71\u201383. doi: 10.1111/j.1471-4159.2011.07476.x.", "ArticleIdList": ["10.1111/j.1471-4159.2011.07476.x", "PMC3276244", "22122681"]}, {"Citation": "Yan R. Stepping closer to treating Alzheimer\u2019s disease patients with BACE1 inhibitor drugs. Transl. Neurodegener. 2016;5 doi: 10.1186/s40035-016-0061-5.", "ArticleIdList": ["10.1186/s40035-016-0061-5", "PMC4944430", "27418961"]}, {"Citation": "Alzforum  Lilly Halts Phase 2 Trial of BACE Inhibitor Due to Liver Toxicity.  [(accessed on 3 August 2020)]; Available online:  https://www.alzforum.org/news/research-news/lilly-halts-phase-2-trial-bace-inhibitor-due-liver-toxicity."}, {"Citation": "Kennedy M.E., Stamford A.W., Chen X., Cox K., Cumming J.N., Dockendorf M.F., Egan M., Ereshefsky L., Hodgson R.A., Hyde L.A., et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-Amyloid in animal models and in Alzheimer\u2019s disease patients. Sci. Transl. Med. 2016;8:363ra150. doi: 10.1126/scitranslmed.aad9704.", "ArticleIdList": ["10.1126/scitranslmed.aad9704", "27807285"]}, {"Citation": "Egan M.F., Kost J., Voss T., Mukai Y., Aisen P.S., Cummings J.L., Tariot P.N., Vellas B., Van Dyck C.H., Boada M., et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N. Engl. J. Med. 2019;380:1408\u20131420. doi: 10.1056/NEJMoa1812840.", "ArticleIdList": ["10.1056/NEJMoa1812840", "PMC6776078", "30970186"]}, {"Citation": "Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992;258:126\u2013129. doi: 10.1126/science.1439760.", "ArticleIdList": ["10.1126/science.1439760", "1439760"]}, {"Citation": "Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid \u03b2-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322\u2013325. doi: 10.1038/359322a0.", "ArticleIdList": ["10.1038/359322a0", "1383826"]}, {"Citation": "De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., et al. A presenilin-1-dependent \u03b3-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518\u2013522. doi: 10.1038/19083.", "ArticleIdList": ["10.1038/19083", "10206645"]}, {"Citation": "Henley D.B., May P.C., Dean R.A., Siemers E.R. Development of semagacestat (LY450139), a functional \u03b3-secretase inhibitor, for the treatment of Alzheimer\u2019s disease. Expert Opin. Pharmacother. 2009;10:1657\u20131664. doi: 10.1517/14656560903044982.", "ArticleIdList": ["10.1517/14656560903044982", "19527190"]}, {"Citation": "Imbimbo B.P. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr. Top. Med. Chem. 2008;8:54\u201361. doi: 10.2174/156802608783334015.", "ArticleIdList": ["10.2174/156802608783334015", "18220933"]}, {"Citation": "Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., Farlow M.R., Galvin J.E., Peskind E.R., Quinn J.F., et al. Phase 2 Safety Trial Targeting Amyloid \u03b2 Production With a \u03b3-Secretase Inhibitor in Alzheimer Disease. Arch. Neurol. 2008;65:1031\u20131038. doi: 10.1001/archneur.65.8.1031.", "ArticleIdList": ["10.1001/archneur.65.8.1031", "PMC2682361", "18695053"]}, {"Citation": "Xia X., Qian S., Soriano S., Wu Y., Fletcher A.M., Wang X.J., Koo E.H., Wu X., Zheng H. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. USA. 2001;98:10863\u201310868. doi: 10.1073/pnas.191284198.", "ArticleIdList": ["10.1073/pnas.191284198", "PMC58565", "11517342"]}, {"Citation": "Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., Hui C., Clevers H., Dotto G.P., Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003;33:416\u2013421. doi: 10.1038/ng1099.", "ArticleIdList": ["10.1038/ng1099", "12590261"]}, {"Citation": "Stanger B.Z., Datar R., Murtaugh L.C., Melton D.A. Direct regulation of intestinal fate by Notch. Proc. Natl. Acad. Sci. USA. 2005;102:12443\u201312448. doi: 10.1073/pnas.0505690102.", "ArticleIdList": ["10.1073/pnas.0505690102", "PMC1194941", "16107537"]}, {"Citation": "Maillard I., Adler S.H., Pear W.S. Notch and the immune system. Immunity. 2003;19:781\u2013791. doi: 10.1016/S1074-7613(03)00325-X.", "ArticleIdList": ["10.1016/S1074-7613(03)00325-X", "14670296"]}, {"Citation": "Bateman R.J., Siemers E.R., Mawuenyega K.G., Wen G., Browning K.R., Sigurdson W.C., Yarasheski K.E., Friedrich S.W., DeMattos R.B., May P.C., et al. A \u03b3-secretase inhibitor decreases amyloid-\u03b2 production in the central nervous system. Ann. Neurol. 2009;66:48\u201354. doi: 10.1002/ana.21623.", "ArticleIdList": ["10.1002/ana.21623", "PMC2730994", "19360898"]}, {"Citation": "Doody R.S., Raman R., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., He F., Sun X., Thomas R.G., et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 2013;369:341\u2013350. doi: 10.1056/NEJMoa1210951.", "ArticleIdList": ["10.1056/NEJMoa1210951", "23883379"]}, {"Citation": "Borgegard T., Gustavsson S., Nilsson C., Parpal S., Klintenberg R., Berg A.-L., Rosqvist S., Serneels L., Svensson S., Olsson F., et al. Alzheimer\u2019s Disease: Presenilin 2-Sparing-Secretase Inhibition Is a Tolerable A Peptide-Lowering Strategy. J. Neurosci. 2012;32:17297\u201317305. doi: 10.1523/JNEUROSCI.1451-12.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.1451-12.2012", "PMC6621836", "23197721"]}, {"Citation": "Zhao B., Yu M., Neitzel M., Marugg J., Jagodzinski J., Lee M., Hu K., Schenk D., Yednock T., Basi G. Identification of \u03b3-Secretase Inhibitor Potency Determinants on Presenilin. J. Biol. Chem. 2008;283:2927\u20132938. doi: 10.1074/jbc.M708870200.", "ArticleIdList": ["10.1074/jbc.M708870200", "18032377"]}, {"Citation": "Serneels L., Van Biervliet J., Craessaerts K., Dejaegere T., Horre K., Van Houtvin T., Esselmann H., Paul S., Schafer M.K., Berezovska O., et al. gamma-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer\u2019s Disease. Science. 2009;324:639\u2013642. doi: 10.1126/science.1171176.", "ArticleIdList": ["10.1126/science.1171176", "PMC2740474", "19299585"]}, {"Citation": "Gillman K.W., Starrett J.E., Parker M.F., Xie K., Bronson J.J., Marcin L.R., McElhone K.E., Bergstrom C.P., Mate R.A., Williams R., et al. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable \u03b3-secretase inhibitor. ACS Med. Chem. Lett. 2010;1:120\u2013124. doi: 10.1021/ml1000239.", "ArticleIdList": ["10.1021/ml1000239", "PMC4007960", "24900185"]}, {"Citation": "Crump C.J., Castro S.V., Wang F., Pozdnyakov N., Ballard T.E., Sisodia S.S., Bales K.R., Johnson D.S., Li Y.-M. BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity. Biochemistry. 2012;51:7209\u20137211. doi: 10.1021/bi301137h.", "ArticleIdList": ["10.1021/bi301137h", "PMC3470910", "22931393"]}, {"Citation": "Hopkins C.R. ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another \u03b3-Secretase Inhibitor Fails in the Clinic. ACS Chem. Neurosci. 2011;2:279\u2013280. doi: 10.1021/cn2000469.", "ArticleIdList": ["10.1021/cn2000469", "PMC3369733", "22778871"]}, {"Citation": "ClinicalTrials.gov  Global Efficacy Study of MPC-7869 to Treat Patients with Alzheimer\u2019s.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00322036."}, {"Citation": "Green R.C., Schneider L.S., Amato D.A., Beelen A.P., Wilcock G., Swabb E.A., Zavitz K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA J. Am. Med. Assoc. 2009;302:2557\u20132564. doi: 10.1001/jama.2009.1866.", "ArticleIdList": ["10.1001/jama.2009.1866", "PMC2902875", "20009055"]}, {"Citation": "ClinicalTrials.gov  Open-label Treatment with MPC-7869 for Patients with Alzheimer\u2019s Who Previously Participated in an MPC-7869 Protocol.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00380276."}, {"Citation": "ClinicalTrials.gov  Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 (CT04)  [(accessed on 3 August 2020)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT01303744."}, {"Citation": "Ereshefsky L., Jhee S., Yen M., Moran S., Pretorius S., Adams J. Cerebrospinal fluid \u03b2-amyloid and dynabridging in Alzheimer\u2019s disease drug development. Biomark. Med. 2009;3:711\u2013721. doi: 10.2217/bmm.09.39.", "ArticleIdList": ["10.2217/bmm.09.39", "20477709"]}, {"Citation": "ClinicalTrials.gov  Study Evaluating the Coadministration of Begacestat and Donepezil.  [(accessed on 3 June 2020)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT00959881."}, {"Citation": "ClinicalTrials.gov  Development of NIC5-15 in the Treatment of Alzheimer\u2019s Disease.  [(accessed on 3 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/results/NCT00470418."}, {"Citation": "ClinicalTrials.gov  A single Site, Randomized, Double-Blind, Placebo Controlled Trial of NIC5-15 in Subjects with Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01928420."}, {"Citation": "Manzano S., Ag\u00fcera L., Aguilar M., Olazar\u00e1n J. A Review on Tramiprosate (Homotaurine) in Alzheimer\u2019s Disease and Other Neurocognitive Disorders. Front. Neurol. 2020;11:614. doi: 10.3389/fneur.2020.00614.", "ArticleIdList": ["10.3389/fneur.2020.00614", "PMC7358344", "32733362"]}, {"Citation": "Gervais F., Paquette J., Morissette C., Krzywkowski P., Yu M., Azzi M., Lacombe D., Kong X., Aman A., Laurin J., et al. Targeting soluble A\u03b2 peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging. 2007;28:537\u2013547. doi: 10.1016/j.neurobiolaging.2006.02.015.", "ArticleIdList": ["10.1016/j.neurobiolaging.2006.02.015", "16675063"]}, {"Citation": "Abushakra S., Porsteinsson A., Vellas B., Cummings J., Gauthier S., Hey J.A., Power A., Hendrix S., Wang P., Shen L., et al. Clinical Benefits of Tramiprosate in Alzheimer\u2019s Disease Are Associated with Higher Number of APOE4 Alleles: The \u201cAPOE4 Gene-Dose Effect\u201d. J. Prev. Alzheimer\u2019s Dis. 2016;3:219\u2013228.", "ArticleIdList": ["29199323"]}, {"Citation": "Kocis P., Tolar M., Yu J., Sinko W., Ray S., Blennow K., Fillit H., Hey J.A. Elucidating the A\u03b242 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer\u2019s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. CNS Drugs. 2017;31:495\u2013509. doi: 10.1007/s40263-017-0434-z.", "ArticleIdList": ["10.1007/s40263-017-0434-z", "PMC5488121", "28435985"]}, {"Citation": "Tolar M., Abushakra S., Sabbagh M. The path forward in Alzheimer\u2019s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer\u2019s Dement. 2020 doi: 10.1016/j.jalz.2019.09.075.", "ArticleIdList": ["10.1016/j.jalz.2019.09.075", "31706733"]}, {"Citation": "McLaurin J.A., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H.L., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., et al. Cyclohexanehexol inhibitors of A\u03b2 aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006;12:801\u2013808. doi: 10.1038/nm1423.", "ArticleIdList": ["10.1038/nm1423", "16767098"]}, {"Citation": "ClinicalTrials.gov  ELND005 in Patients with Mild to Moderate Alzheimer\u2019s Disease.  [(accessed on 18 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/study/NCT00568776."}, {"Citation": "Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 2008;15:558\u2013566. doi: 10.1038/nsmb.1437.", "ArticleIdList": ["10.1038/nsmb.1437", "18511942"]}, {"Citation": "Lopez Del Amo J.M., Fink U., Dasari M., Grelle G., Wanker E.E., Bieschke J., Reif B. Structural properties of EGCG-induced, nontoxic Alzheimer\u2019s disease A\u03b2 oligomers. J. Mol. Biol. 2012;421:517\u2013524. doi: 10.1016/j.jmb.2012.01.013.", "ArticleIdList": ["10.1016/j.jmb.2012.01.013", "22300765"]}, {"Citation": "Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001;21:8370\u20138377. doi: 10.1523/JNEUROSCI.21-21-08370.2001.", "ArticleIdList": ["10.1523/JNEUROSCI.21-21-08370.2001", "PMC6762797", "11606625"]}, {"Citation": "Yanagisawa D., Taguchi H., Yamamoto A., Shirai N., Hirao K., Tooyama I. Curcuminoid binds to amyloid-\u03b21-42 oligomer and fibril. J. Alzheimer\u2019s Dis. 2011;24:33\u201342. doi: 10.3233/JAD-2011-102100.", "ArticleIdList": ["10.3233/JAD-2011-102100", "21335654"]}, {"Citation": "Liu K.N., Lai C.M., Lee Y.T., Wang S.N., Chen R.P.Y., Jan J.S., Liu H.S., Wang S.S.S. Curcumin\u2019s pre-incubation temperature affects its inhibitory potency toward amyloid fibrillation and fibril-induced cytotoxicity of lysozyme. Biochim. Biophys. Acta Gen. Subj. 2012;1820:1774\u20131786. doi: 10.1016/j.bbagen.2012.07.012.", "ArticleIdList": ["10.1016/j.bbagen.2012.07.012", "22884915"]}, {"Citation": "Hamaguchi T., Ono K., Murase A., Yamada M. Phenolic compounds prevent Alzheimer\u2019s pathology through different effects on the amyloid-\u03b2 aggregation pathway. Am. J. Pathol. 2009;175:2557\u20132565. doi: 10.2353/ajpath.2009.090417.", "ArticleIdList": ["10.2353/ajpath.2009.090417", "PMC2789642", "19893028"]}, {"Citation": "Caesar I., Jonson M., Nilsson K.P.R., Thor S., Hammarstr\u00f6m P. Curcumin Promotes A-beta Fibrillation and Reduces Neurotoxicity in Transgenic Drosophila. PLoS ONE. 2012;7:e31424. doi: 10.1371/journal.pone.0031424.", "ArticleIdList": ["10.1371/journal.pone.0031424", "PMC3278449", "22348084"]}, {"Citation": "Ringman J.M., Frautschy S.A., Teng E., Begum A.N., Bardens J., Beigi M., Gylys K.H., Badmaev V., Heath D.D., Apostolova L.G., et al. Oral curcumin for Alzheimer\u2019s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer\u2019s Res. Ther. 2012;4:43. doi: 10.1186/alzrt146.", "ArticleIdList": ["10.1186/alzrt146", "PMC3580400", "23107780"]}, {"Citation": "Uddin M.S., Al Mamun A., Kabir M.T., Ahmad J., Jeandet P., Sarwar M.S., Ashraf G.M., Aleya L. Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration. Eur. J. Pharmacol. 2020:173412. doi: 10.1016/j.ejphar.2020.173412.", "ArticleIdList": ["10.1016/j.ejphar.2020.173412", "32771668"]}, {"Citation": "Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer\u2019s disease amyloid-\u03b2 peptides. J. Biol. Chem. 2005;280:37377\u201337382. doi: 10.1074/jbc.M508246200.", "ArticleIdList": ["10.1074/jbc.M508246200", "16162502"]}, {"Citation": "Jeon S.Y., Kwon S.H., Seong Y.H., Bae K., Hur J.M., Lee Y.Y., Suh D.Y., Song K.S. \u03b2-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine. 2007;14:403\u2013408. doi: 10.1016/j.phymed.2006.09.003.", "ArticleIdList": ["10.1016/j.phymed.2006.09.003", "17084604"]}, {"Citation": "Huang T.C., Lu K.T., Wo Y.Y.P., Wu Y.J., Yang Y.L. Resveratrol protects rats from A\u03b2-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS ONE. 2011;6:e29102. doi: 10.1371/journal.pone.0029102.", "ArticleIdList": ["10.1371/journal.pone.0029102", "PMC3248406", "22220203"]}, {"Citation": "Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-\u03b2 peptide metabolism. J. Biol. Chem. 2010;285:9100\u20139113. doi: 10.1074/jbc.M109.060061.", "ArticleIdList": ["10.1074/jbc.M109.060061", "PMC2838330", "20080969"]}, {"Citation": "Turner R.S., Thomas R.G., Craft S., Van Dyck C.H., Mintzer J., Reynolds B.A., Brewer J.B., Rissman R.A., Raman R., Aisen P.S. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383\u20131391. doi: 10.1212/WNL.0000000000002035.", "ArticleIdList": ["10.1212/WNL.0000000000002035", "PMC4626244", "26362286"]}, {"Citation": "Zhu C.W., Grossman H., Neugroschl J., Parker S., Burden A., Luo X., Sano M. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer\u2019s disease: A pilot study. Alzheimer\u2019s Dement. Transl. Res. Clin. Interv. 2018;4:609\u2013616. doi: 10.1016/j.trci.2018.09.009.", "ArticleIdList": ["10.1016/j.trci.2018.09.009", "PMC6240843", "30480082"]}, {"Citation": "Shimmyo Y., Kihara T., Akaike A., Niidome T., Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim. Biophys. Acta Gen. Subj. 2008;1780:819\u2013825. doi: 10.1016/j.bbagen.2008.01.017.", "ArticleIdList": ["10.1016/j.bbagen.2008.01.017", "18295609"]}, {"Citation": "Lu J., Wu D.M., Zheng Y.L., Hu B., Zhang Z.F., Shan Q., Zheng Z.H., Liu C.M., Wang Y.J. Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. J. Pathol. 2010;222:199\u2013212. doi: 10.1002/path.2754.", "ArticleIdList": ["10.1002/path.2754", "20690163"]}, {"Citation": "Ansari M.A., Abdul H.M., Joshi G., Opii W.O., Butterfield D.A. Protective effect of quercetin in primary neurons against A\u03b2(1-42): Relevance to Alzheimer\u2019s disease. J. Nutr. Biochem. 2009;20:269\u2013275. doi: 10.1016/j.jnutbio.2008.03.002.", "ArticleIdList": ["10.1016/j.jnutbio.2008.03.002", "PMC2737260", "18602817"]}, {"Citation": "Pocernich C.P., Lange M.L.B., Sultana R., Butterfield D.A. Nutritional approaches to modulate oxidative stress in Alzheimer\u2019s disease. Curr. Alzheimer Res. 2011;8:452\u2013469. doi: 10.2174/156720511796391908.", "ArticleIdList": ["10.2174/156720511796391908", "21605052"]}, {"Citation": "Kim H., Park B.S., Lee K.G., Cheol Y.C., Sung S.J., Kim Y.H., Lee S.E. Effects of naturally occurring compounds on fibril formation and oxidative stress of \u03b2-amyloid. J. Agric. Food Chem. 2005;53:8537\u20138541. doi: 10.1021/jf051985c.", "ArticleIdList": ["10.1021/jf051985c", "16248550"]}, {"Citation": "Shimmyo Y., Kihara T., Akaike A., Niidome T., Sugimoto H. Multifunction of myricetin on A\u03b2: Neuroprotection via a conformational change of A\u03b2 and reduction of A\u03b2 via the interference of secretases. J. Neurosci. Res. 2008;86:368\u2013377. doi: 10.1002/jnr.21476.", "ArticleIdList": ["10.1002/jnr.21476", "17722071"]}, {"Citation": "Uddin M.S., Kabir M.T. Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease. Springer; Singapore: 2019. Oxidative Stress in Alzheimer\u2019s Disease: Molecular Hallmarks of Underlying Vulnerability; pp. 91\u2013115."}, {"Citation": "Desai V., Kaler S.G. Role of copper in human neurological disorders. Am. J. Clin. Nutr. 2008;88:855S\u2013858S. doi: 10.1093/ajcn/88.3.855S.", "ArticleIdList": ["10.1093/ajcn/88.3.855S", "18779308"]}, {"Citation": "Bush A.I. Drug development based on the metals hypothesis of Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 2008;15:223\u2013240. doi: 10.3233/JAD-2008-15208.", "ArticleIdList": ["10.3233/JAD-2008-15208", "18953111"]}, {"Citation": "Faller P., Hureau C., Berthoumieu O. Role of metal ions in the self-assembly of the Alzheimer\u2019s amyloid-\u03b2 peptide. Inorg. Chem. 2013;52:12193\u201312206. doi: 10.1021/ic4003059.", "ArticleIdList": ["10.1021/ic4003059", "23607830"]}, {"Citation": "Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer\u2019s disease senile plaques. J. Neurol. Sci. 1998;158:47\u201352. doi: 10.1016/S0022-510X(98)00092-6.", "ArticleIdList": ["10.1016/S0022-510X(98)00092-6", "9667777"]}, {"Citation": "House E., Collingwood J., Khan A., Korchazkina O., Berthon G., Exley C. Aluminium, iron, zinc and copper Influence the in vitro formation of amyloid fibrils of A\u03b242 in a manner which may have consequences for metal chelation therapy in Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 2004;6:291\u2013301. doi: 10.3233/JAD-2004-6310.", "ArticleIdList": ["10.3233/JAD-2004-6310", "15201484"]}, {"Citation": "Khan A., Dobson J.P., Exley C. Redox cycling of iron by A\u03b242. Free Radic. Biol. Med. 2006;40:557\u2013569. doi: 10.1016/j.freeradbiomed.2005.09.013.", "ArticleIdList": ["10.1016/j.freeradbiomed.2005.09.013", "16458186"]}, {"Citation": "Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., et al. Rapid Restoration of Cognition in Alzheimer\u2019s Transgenic Mice with 8-Hydroxy Quinoline Analogs is Associated with Decreased Interstitial A\u03b2. Neuron. 2008;59:43\u201355. doi: 10.1016/j.neuron.2008.06.018.", "ArticleIdList": ["10.1016/j.neuron.2008.06.018", "18614028"]}, {"Citation": "Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., et al. PBT2 rapidly improves cognition in alzheimer\u2019s disease: Additional phase II analyses. J. Alzheimer\u2019s Dis. 2010;20:509\u2013516. doi: 10.3233/JAD-2010-1390.", "ArticleIdList": ["10.3233/JAD-2010-1390", "20164561"]}, {"Citation": "Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA. 1997;94:9866\u20139868. doi: 10.1073/pnas.94.18.9866.", "ArticleIdList": ["10.1073/pnas.94.18.9866", "PMC23283", "9275217"]}, {"Citation": "Sayre L.M., Perry G., Harris P.L.R., Liu Y., Schubert K.A., Smith M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer\u2019s disease: A central role for bound transition metals. J. Neurochem. 2000;74:270\u2013279. doi: 10.1046/j.1471-4159.2000.0740270.x.", "ArticleIdList": ["10.1046/j.1471-4159.2000.0740270.x", "10617129"]}, {"Citation": "Suh S.W., Jensen K.B., Jensen M.S., Silva D.S., Kesslak P.J., Danscher G., Frederickson C.J. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer\u2019s diseased brains. Brain Res. 2000;852:274\u2013278. doi: 10.1016/S0006-8993(99)02096-X.", "ArticleIdList": ["10.1016/S0006-8993(99)02096-X", "10678753"]}, {"Citation": "Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., Carey P.R. Metal binding and oxidation of amyloid-\u03b2 within isolated senile plaque cores: Raman microscopic evidence. Biochemistry. 2003;42:2768\u20132773. doi: 10.1021/bi0272151.", "ArticleIdList": ["10.1021/bi0272151", "12627941"]}, {"Citation": "Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L.R., Siedlak S.L., Tabaton M., Perry G. Amyloid-\u03b2 Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. J. Neurochem. 2002;70:2212\u20132215. doi: 10.1046/j.1471-4159.1998.70052212.x.", "ArticleIdList": ["10.1046/j.1471-4159.1998.70052212.x", "9572310"]}, {"Citation": "Lee J.Y., Mook-Jung I., Koh J.Y. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J. Neurosci. 1999;19:RC10. doi: 10.1523/JNEUROSCI.19-11-j0002.1999.", "ArticleIdList": ["10.1523/JNEUROSCI.19-11-j0002.1999", "PMC6782620", "10341271"]}, {"Citation": "Bush A.I., Pettingell W.H., Multhaup G., Paradis M.D., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer A\u03b2 amyloid formation by zinc. Science. 1994;265:1464\u20131467. doi: 10.1126/science.8073293.", "ArticleIdList": ["10.1126/science.8073293", "8073293"]}, {"Citation": "Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Bacarra N.M.E., Romano D.M., Hartshorn M.A., Tanzi R.E., Bush A.I. Dramatic aggregation of alzheimer by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 1998;273:12817\u201312826. doi: 10.1074/jbc.273.21.12817.", "ArticleIdList": ["10.1074/jbc.273.21.12817", "9582309"]}, {"Citation": "Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., Tanzi R.E., Bush A.I. Characterization of copper interactions with Alzheimer amyloid \u03b2 peptides: Identification of an attomolar-affinity copper binding site on amyloid \u03b21-42. J. Neurochem. 2000;75:1219\u20131233. doi: 10.1046/j.1471-4159.2000.0751219.x.", "ArticleIdList": ["10.1046/j.1471-4159.2000.0751219.x", "10936205"]}, {"Citation": "Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S., Beyreuther K., Barrow C.J., Masters C.L., Bush A.I., Barnham K.J. Alzheimer\u2019s Disease Amyloid-\u03b2 Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits. J. Biol. Chem. 2001;276:20466\u201320473. doi: 10.1074/jbc.M100175200.", "ArticleIdList": ["10.1074/jbc.M100175200", "11274207"]}, {"Citation": "Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D.A., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., et al. Cu(II) potentiation of Alzheimer a\u03b2 neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 1999;274:37111\u201337116. doi: 10.1074/jbc.274.52.37111.", "ArticleIdList": ["10.1074/jbc.274.52.37111", "10601271"]}, {"Citation": "Bayer T.A., Sch\u00e4fer S., Simons A., Kemmling A., Kamer T., Tepest R., Eckert A., Sch\u00fcssel K., Eikenberg O., Sturchler-Pierrat C., et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid A\u03b2 production in APP23 transgenic mice. Proc. Natl. Acad. Sci. USA. 2003;100:14187\u201314192. doi: 10.1073/pnas.2332818100.", "ArticleIdList": ["10.1073/pnas.2332818100", "PMC283567", "14617773"]}, {"Citation": "Phinney A.L., Drisaldi B., Schmidt S.D., Lugowski S., Coronado V., Liang Y., Horne P., Yang J., Sekoulidis J., Coomaraswamy J., et al. In vivo reduction of amyloid-\u03b2 by a mutant copper transporter. Proc. Natl. Acad. Sci. USA. 2003;100:14193\u201314198. doi: 10.1073/pnas.2332851100.", "ArticleIdList": ["10.1073/pnas.2332851100", "PMC283568", "14617772"]}, {"Citation": "Maynard C.J., Cappai R., Volitakis I., Cherny R.A., White A.R., Beyreuther K., Masters C.L., Bush A.I., Li Q.X. Overexpression of Alzheimer\u2019s disease amyloid-\u03b2 opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 2002;277:44670\u201344676. doi: 10.1074/jbc.M204379200.", "ArticleIdList": ["10.1074/jbc.M204379200", "12215434"]}, {"Citation": "Borchardt T., Camakaris J., Cappai R., Masters C.L., Beyreuther K., Multhaup G. Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem. J. 1999;344 Pt2:461\u2013467. doi: 10.1042/bj3440461.", "ArticleIdList": ["10.1042/bj3440461", "PMC1220664", "10567229"]}, {"Citation": "Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., et al. Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916\u2013919. doi: 10.1038/78682.", "ArticleIdList": ["10.1038/78682", "10932230"]}, {"Citation": "Vasilevko V., Xu F., Previti M.L., Van Nostrand W.E., Cribbs D.H. Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid- in CNS of Tg-SwDI Transgenic Mice. J. Neurosci. 2007;27:13376\u201313383. doi: 10.1523/JNEUROSCI.2788-07.2007.", "ArticleIdList": ["10.1523/JNEUROSCI.2788-07.2007", "PMC6673094", "18057195"]}, {"Citation": "Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., et al. Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173\u2013177. doi: 10.1038/22124.", "ArticleIdList": ["10.1038/22124", "10408445"]}, {"Citation": "Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Issazadeh S., Hancock W.W., Selkoe D.J. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer\u2019s disease. Ann. Neurol. 2000;48:567\u2013579. doi: 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W.", "ArticleIdList": ["10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W", "11026440"]}, {"Citation": "Kabir M.T., Uddin M.S., Mathew B., Das P.K., Perveen A., Ashraf G.M. Emerging Promise of Immunotherapy for Alzheimer\u2019s Disease: A New Hope for the Development of Alzheimer\u2019s Vaccine. Curr. Top. Med. Chem. 2020;20:1214\u20131234. doi: 10.2174/1568026620666200422105156.", "ArticleIdList": ["10.2174/1568026620666200422105156", "32321405"]}, {"Citation": "Lambracht-Washington D., Rosenberg R.N. Advances in the development of vaccines for alzheimer\u2019s disease. Discov. Med. 2013;15:319\u2013326.", "ArticleIdList": ["PMC3696351", "23725605"]}, {"Citation": "Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-\u0392 immunotherapy? Nat. Rev. Neurol. 2010;6:108\u2013119. doi: 10.1038/nrneurol.2009.219.", "ArticleIdList": ["10.1038/nrneurol.2009.219", "PMC2864089", "20140000"]}, {"Citation": "Wiessner C., Wiederhold K.H., Tissot A.C., Frey P., Danner S., Jacobson L.H., Jennings G.T., L\u00fc\u00f6nd R., Ortmann R., Reichwald J., et al. The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 2011;31:9323\u20139331. doi: 10.1523/JNEUROSCI.0293-11.2011.", "ArticleIdList": ["10.1523/JNEUROSCI.0293-11.2011", "PMC6623465", "21697382"]}, {"Citation": "Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., Maguire R.P., Blennow K., Lundmark J., Staufenbiel M., et al. Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11:597\u2013604. doi: 10.1016/S1474-4422(12)70140-0.", "ArticleIdList": ["10.1016/S1474-4422(12)70140-0", "22677258"]}, {"Citation": "Winblad B., Minthon L., Floesser A. Results of the first-in-man study with the active A\u03b2immunotherapy CAD106 in Alzheimer patients. Alzheimer\u2019s Dement. 2009;5:P113\u2013P114. doi: 10.1016/j.jalz.2009.05.356.", "ArticleIdList": ["10.1016/j.jalz.2009.05.356"]}, {"Citation": "Schneeberger A., Mandler M., Otawa O., Zauner W., Mattner F., Schmidt W. Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD)\u2014From concept to clinical testing. J. Nutr. Health Aging. 2009;13:264\u2013267. doi: 10.1007/s12603-009-0070-5.", "ArticleIdList": ["10.1007/s12603-009-0070-5", "19262965"]}, {"Citation": "Khandelwal P.J., Herman A.M., Moussa C.E.-H. Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 2011;238:1\u201311. doi: 10.1016/j.jneuroim.2011.07.002.", "ArticleIdList": ["10.1016/j.jneuroim.2011.07.002", "PMC3176984", "21820744"]}, {"Citation": "Winblad B., Graf A., Riviere M.-E., Andreasen N., Ryan J. Active immunotherapy options for Alzheimer\u2019s disease. Alzheimers. Res. Ther. 2014;6:7. doi: 10.1186/alzrt237.", "ArticleIdList": ["10.1186/alzrt237", "PMC3979042", "24476230"]}, {"Citation": "Schneeberger A., Hendrix S., Mandler M., Ellison N., B\u00fcrger V., Brunner M., Fr\u00f6lich L., Mimica N., Hort J., Rainer M., et al. Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE\u00ae AD02 in Patients with Early Alzheimer\u2019s Disease. J. Prev. Alzheimer\u2019s Dis. 2015;2:103\u2013114.", "ArticleIdList": ["29231230"]}, {"Citation": "Alzforum  Vanutide Cridificar.  [(accessed on 3 August 2020)]; Available online:  https://www.alzforum.org/therapeutics/vanutide-cridificar."}, {"Citation": "ClinicalTrials.gov  Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity of ACC-001 in Japanese Subjects with Mild to Moderate Alzheimer\u2019s Disease.  [(accessed on 18 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01238991."}, {"Citation": "ClinicalTrials.gov  Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects with Mild to Moderate Alzheimer\u2019s Disease.  [(accessed on 18 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00479557."}, {"Citation": "ClinicalTrials.gov  Study Evaluating ACC-001 in Subjects with Mild to Moderate Alzheimer\u2019s Disease.  [(accessed on 18 June 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00498602."}, {"Citation": "Wilcock D.M., Gharkholonarehe N., Van Nostrand W.E., Davis J., Vitek M.P., Colton C.A. Amyloid Reduction by Amyloid- Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer\u2019s Disease. J. Neurosci. 2009;29:7957\u20137965. doi: 10.1523/JNEUROSCI.1339-09.2009.", "ArticleIdList": ["10.1523/JNEUROSCI.1339-09.2009", "PMC2871319", "19553436"]}, {"Citation": "Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. A\u03b2 Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome. Neuron. 2004;43:321\u2013332. doi: 10.1016/j.neuron.2004.07.003.", "ArticleIdList": ["10.1016/j.neuron.2004.07.003", "15294141"]}, {"Citation": "Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., et al. Amyloid \u03b2 protein immunotherapy neutralizes A\u03b2 oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005;11:556\u2013561. doi: 10.1038/nm1234.", "ArticleIdList": ["10.1038/nm1234", "15834427"]}, {"Citation": "Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., Sabbagh M., Honig L.S., Porsteinsson A.P., Ferris S., et al. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 2014;370:322\u2013333. doi: 10.1056/NEJMoa1304839.", "ArticleIdList": ["10.1056/NEJMoa1304839", "PMC4159618", "24450891"]}, {"Citation": "Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., et al. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer\u2019s Disease. N. Engl. J. Med. 2014;370:311\u2013321. doi: 10.1056/NEJMoa1312889.", "ArticleIdList": ["10.1056/NEJMoa1312889", "24450890"]}, {"Citation": "ClinicalTrials.gov  Study Evaluating the Safety, Tolerability and Efficacy of PF-04360365 in Adults with Probable Cerebral Amyloid Angiopathy.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01821118."}, {"Citation": "Samadi H., Sultzer D. Solanezumab for Alzheimer\u2019s disease. Expert Opin. Biol. Ther. 2011;11:787\u2013798. doi: 10.1517/14712598.2011.578573.", "ArticleIdList": ["10.1517/14712598.2011.578573", "21504387"]}, {"Citation": "Bohrmann B., Baumann K., Benz J., Gerber F., Huber W., Knoflach F., Messer J., Oroszlan K., Rauchenberger R., Richter W.F., et al. Gantenerumab: A novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J. Alzheimer\u2019s Dis. 2012;28:49\u201369. doi: 10.3233/JAD-2011-110977.", "ArticleIdList": ["10.3233/JAD-2011-110977", "21955818"]}, {"Citation": "Ostrowitzki S., Deptula D., Thurfjell L., Barkhof F., Bohrmann B., Brooks D.J., Klunk W.E., Ashford E., Yoo K., Xu Z.X., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 2012;69:198\u2013207. doi: 10.1001/archneurol.2011.1538.", "ArticleIdList": ["10.1001/archneurol.2011.1538", "21987394"]}, {"Citation": "ClinicalTrials.gov  Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or with a Type of Early Onset Alzheimer\u2019s Disease Caused by a Genetic Mutation.  [(accessed on 3 August 2020)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT01760005."}, {"Citation": "Washington University School of Medicine  The Dominantly Inherited Alzheimer Network: Clinical Trial.  [(accessed on 3 August 2020)]; Available online:  https://dian.wustl.edu/our-research/clinical-trial/"}, {"Citation": "Alzheimer\u2019s News Today  Solanezumab.  [(accessed on 3 August 2020)]; Available online:  https://alzheimersnewstoday.com/solanezumab/"}, {"Citation": "Adolfsson O., Pihlgren M., Toni N., Varisco Y., Buccarello A.L., Antoniello K., Lohmann S., Piorkowska K., Gafner V., Atwal J.K., et al. An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique A\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J. Neurosci. 2012;32:9677\u20139689. doi: 10.1523/JNEUROSCI.4742-11.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.4742-11.2012", "PMC6622286", "22787053"]}, {"Citation": "Freeman G.B., Brown T.P., Wallace K., Bales K.R. Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in Aged Tg2576 mice. Curr. Alzheimer Res. 2012;9:1059\u20131068. doi: 10.2174/156720512803569064.", "ArticleIdList": ["10.2174/156720512803569064", "22631613"]}, {"Citation": "La Porte S.L., Bollini S.S., Lanz T.A., Abdiche Y.N., Rusnak A.S., Ho W.H., Kobayashi D., Harrabi O., Pappas D., Mina E.W., et al. Structural basis of C-terminal \u03b2-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease. J. Mol. Biol. 2012;421:525\u2013536. doi: 10.1016/j.jmb.2011.11.047.", "ArticleIdList": ["10.1016/j.jmb.2011.11.047", "22197375"]}, {"Citation": "ClinicalTrials.gov  Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A\u03b2 IgG1 mAb) in Participants with Prodromal or Mild Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01677572."}, {"Citation": "ClinicalTrials.gov  221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02477800."}, {"Citation": "ClinicalTrials.gov  221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/results/NCT02484547."}, {"Citation": "Biogen  About Aducanumab.  [(accessed on 3 August 2020)]; Available online:  https://biogenalzheimers.com/about-aducanumab/"}, {"Citation": "Biogen  Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-completes-submission-biologics-license-application-fda."}, {"Citation": "Logovinsky V., Satlin A., Lai R., Swanson C., Kaplow J., Osswald G., Basun H., Lannfelt L. Safety and tolerability of BAN2401\u2014A clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody. Alzheimers. Res. Ther. 2016;8:14. doi: 10.1186/s13195-016-0181-2.", "ArticleIdList": ["10.1186/s13195-016-0181-2", "PMC4822297", "27048170"]}, {"Citation": "Tucker S., M\u00f6ller C., Tegerstedt K., Lord A., Laudon H., Sj\u00f6dahl J., S\u00f6derberg L., Spens E., Sahlin C., Waara E.R., et al. The murine Version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Mice. J. Alzheimer\u2019s Dis. 2015;43:575\u2013588. doi: 10.3233/JAD-140741.", "ArticleIdList": ["10.3233/JAD-140741", "25096615"]}, {"Citation": "S\u00f6llvander S., Nikitidou E., Gallasch L., Zy\u015bk M., S\u00f6derberg L., Sehlin D., Lannfelt L., Erlandsson A. The A\u03b2 protofibril selective antibody mAb158 prevents accumulation of A\u03b2 in astrocytes and rescues neurons from A\u03b2-induced cell death. J. Neuroinflammation. 2018;15:98. doi: 10.1186/s12974-018-1134-4.", "ArticleIdList": ["10.1186/s12974-018-1134-4", "PMC5875007", "29592816"]}, {"Citation": "ClinicalTrials.gov  A Study to Confirm Safety and Efficacy of BAN2401 in Participants with Early Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03887455."}, {"Citation": "Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer\u2019s A\u03b2 Peptide. Neuron. 2004;43:605\u2013608. doi: 10.1016/j.neuron.2004.08.024.", "ArticleIdList": ["10.1016/j.neuron.2004.08.024", "15339642"]}, {"Citation": "Deane R., Wu Z., Zlokovic B. V RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid -Peptide Clearance through Transport across the Blood-Brain Barrier. Stroke. 2004;35:2628\u20132631. doi: 10.1161/01.STR.0000143452.85382.d1.", "ArticleIdList": ["10.1161/01.STR.0000143452.85382.d1", "15459432"]}, {"Citation": "Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer\u2019s disease. Neurotherapeutics. 2008;5:409\u2013414. doi: 10.1016/j.nurt.2008.05.011.", "ArticleIdList": ["10.1016/j.nurt.2008.05.011", "PMC2536515", "18625452"]}, {"Citation": "Deane R., Zlokovic B. V Role of the blood-brain barrier in the pathogenesis of Alzheimer\u2019s disease. Curr. Alzheimer Res. 2007;4:191\u2013197. doi: 10.2174/156720507780362245.", "ArticleIdList": ["10.2174/156720507780362245", "17430246"]}, {"Citation": "Deane R., Sagare A., Zlokovic B. V The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer\u2019s disease. Curr. Pharm. Des. 2008;14:1601\u20131605. doi: 10.2174/138161208784705487.", "ArticleIdList": ["10.2174/138161208784705487", "PMC2895311", "18673201"]}, {"Citation": "Marques M.A., Kulstad J.J., Savard C.E., Green P.S., Lee S.P., Craft S., Watson G.S., Cook D.G. Peripheral Amyloid-\u03b2 Levels Regulate Amyloid-\u03b2 Clearance from the Central Nervous System. J. Alzheimer\u2019s Dis. 2009;16:325\u2013329. doi: 10.3233/JAD-2009-0964.", "ArticleIdList": ["10.3233/JAD-2009-0964", "PMC3066174", "19221422"]}, {"Citation": "Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., Marky A., Lenting P.J., Wu Z., Zarcone T., et al. Clearance of amyloid-\u03b2 by circulating lipoprotein receptors. Nat. Med. 2007;13:1029\u20131031. doi: 10.1038/nm1635.", "ArticleIdList": ["10.1038/nm1635", "PMC2936449", "17694066"]}, {"Citation": "Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.-M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Du Yan S., et al. RAGE and amyloid beta interactions: Atomic force microscopy and molecular modeling. Biochim. Biophys. Acta Mol. Basis Dis. 2005;1741:199\u2013205. doi: 10.1016/j.bbadis.2005.03.014.", "ArticleIdList": ["10.1016/j.bbadis.2005.03.014", "15882940"]}, {"Citation": "Du Yan S., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., et al. RAGE and amyloid-\u03b2 peptide neurotoxicity in Alzheimer\u2019s disease. Nature. 1996;382:685\u2013691. doi: 10.1038/382685a0.", "ArticleIdList": ["10.1038/382685a0", "8751438"]}, {"Citation": "Stern D.M., Du Yan S., Yan S.F., Schmidt A.M. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev. 2002;1:1\u201315. doi: 10.1016/S0047-6374(01)00366-9.", "ArticleIdList": ["10.1016/S0047-6374(01)00366-9", "12039445"]}, {"Citation": "Zlokovic B.V. Cerebrovascular transport of Alzheimer\u2019s amyloid beta and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996;59:1483\u20131497. doi: 10.1016/0024-3205(96)00310-4.", "ArticleIdList": ["10.1016/0024-3205(96)00310-4", "8890929"]}, {"Citation": "Wang W., Bodles-Brakhop A.M., Barger S.W. A role for P-glycoprotein in clearance of Alzheimer amyloid \u03b2-peptide from the brain. Curr. Alzheimer Res. 2016;13:615\u2013620. doi: 10.2174/1567205013666160314151012.", "ArticleIdList": ["10.2174/1567205013666160314151012", "PMC5102249", "26971931"]}, {"Citation": "Park J.H., Strittmatter S.M. Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer\u2019s transgenic mice. Curr. Alzheimer Res. 2007;4:568\u2013570. doi: 10.2174/156720507783018235.", "ArticleIdList": ["10.2174/156720507783018235", "PMC2846284", "18220524"]}, {"Citation": "Tang B.L., Liou Y.C. Novel modulators of amyloid-\u03b2 precursor protein processing. J. Neurochem. 2007;100:314\u2013323. doi: 10.1111/j.1471-4159.2006.04215.x.", "ArticleIdList": ["10.1111/j.1471-4159.2006.04215.x", "17241154"]}, {"Citation": "Yamazaki Y., Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer\u2019s disease. Int. J. Mol. Sci. 2017;18:1965. doi: 10.3390/ijms18091965.", "ArticleIdList": ["10.3390/ijms18091965", "PMC5618614", "28902142"]}, {"Citation": "Mao P., Manczak M., Calkins M.J., Truong Q., Reddy T.P., Reddy A.P., Shirendeb U., Lo H.-H., Rabinovitch P.S., Reddy P.H. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid production and BACE1 in a mouse model of Alzheimer\u2019s disease: Implications for neuroprotection and lifespan extension. Hum. Mol. Genet. 2012;21:2973\u20132990. doi: 10.1093/hmg/dds128.", "ArticleIdList": ["10.1093/hmg/dds128", "PMC3373244", "22492996"]}, {"Citation": "Uddin M.S., Kabir M.T., Al Mamun A., Barreto G.E., Rashid M., Perveen A., Ashraf G.M. Pharmacological approaches to mitigate neuroinflammation in Alzheimer\u2019s disease. Int. Immunopharmacol. 2020;84:106479. doi: 10.1016/j.intimp.2020.106479.", "ArticleIdList": ["10.1016/j.intimp.2020.106479", "32353686"]}, {"Citation": "Carret-Rebillat A.-S., Pace C., Gourmaud S., Ravasi L., Montagne-Stora S., Longueville S., Tible M., Sudol E., Chang R.C.-C., Paquet C., et al. Neuroinflammation and A\u03b2 accumulation linked to systemic inflammation are decreased by genetic PKR down-regulation. Sci. Rep. 2015;5:8489. doi: 10.1038/srep08489.", "ArticleIdList": ["10.1038/srep08489", "PMC4330547", "25687824"]}, {"Citation": "Cai H.-Y., Yang J.-T., Wang Z.-J., Zhang J., Yang W., Wu M.-N., Qi J.-S. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer\u2019s disease. Biochem. Biophys. Res. Commun. 2018;495:1034\u20131040. doi: 10.1016/j.bbrc.2017.11.114.", "ArticleIdList": ["10.1016/j.bbrc.2017.11.114", "29175324"]}, {"Citation": "Mullane K., Williams M. Alzheimer\u2019s disease (AD) therapeutics \u2013 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochem. Pharmacol. 2018;158:359\u2013375. doi: 10.1016/j.bcp.2018.09.026.", "ArticleIdList": ["10.1016/j.bcp.2018.09.026", "30273553"]}, {"Citation": "Scheltens P., Blennow K., Breteler M.M.B., de Strooper B., Frisoni G.B., Salloway S., Van der Flier W.M. Alzheimer\u2019s disease. Lancet. 2016;388:505\u2013517. doi: 10.1016/S0140-6736(15)01124-1.", "ArticleIdList": ["10.1016/S0140-6736(15)01124-1", "26921134"]}, {"Citation": "Coric V., Salloway S., Van Dyck C.H., Dubois B., Andreasen N., Brody M., Curtis C., Soininen H., Thein S., Shiovitz T., et al. Targeting prodromal Alzheimer disease with avagacestat: A randomized clinical trial. J. Am. Med Assoc. Neurol. 2015;72:1324\u20131333. doi: 10.1001/jamaneurol.2015.0607.", "ArticleIdList": ["10.1001/jamaneurol.2015.0607", "26414022"]}, {"Citation": "Timmers M., Streffer J.R., Russu A., Tominaga Y., Shimizu H., Shiraishi A., Tatikola K., Smekens P., B\u00f6rjesson-Hanson A., Andreasen N., et al. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: Randomized, double-blind, placebo-controlled study. Alzheimer\u2019s Res. Ther. 2018;10:85. doi: 10.1186/s13195-018-0415-6.", "ArticleIdList": ["10.1186/s13195-018-0415-6", "PMC6106931", "30134967"]}, {"Citation": "FierceBiotech  Janssen Drops the BACE as Alzheimer\u2019s Candidate Joins Fail List.  [(accessed on 3 August 2020)]; Available online:  https://www.fiercebiotech.com/biotech/janssen-drops-bace-as-alzheimer-s-candidate-joins-fail-list."}, {"Citation": "Janssen  Update on Janssen\u2019s BACE Inhibitor Program Regarding the Dominantly Inherited Alzheimer\u2019s Network Trial (DIAN-TU)  [(accessed on 3 August 2020)]; Available online:  https://www.janssen.com/neuroscience/update-janssens-bace-inhibitor-program-regarding-DIAN-TU."}, {"Citation": "ClinicalTrials.gov  A Study of Lanabecestat (LY3314814) in Early Alzheimer\u2019s Disease Dementia.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02972658."}, {"Citation": "Cebers G., Alexander R.C., Haeberlein S.B., Han D., Goldwater R., Ereshefsky L., Olsson T., Ye N., Rosen L., Russell M., et al. AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer\u2019s Disease. J. Alzheimer\u2019s Dis. 2017;55:1039\u20131053. doi: 10.3233/JAD-160701.", "ArticleIdList": ["10.3233/JAD-160701", "27767991"]}, {"Citation": "Eketj\u00e4ll S., Janson J., Kaspersson K., Bogstedt A., Jeppsson F., F\u00e4lting J., Haeberlein S.B., Kugler A.R., Alexander R.C., Cebers G. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J. Alzheimer\u2019s Dis. 2016;50:1109\u20131123. doi: 10.3233/JAD-150834.", "ArticleIdList": ["10.3233/JAD-150834", "PMC4927864", "26890753"]}, {"Citation": "Egan M.F., Kost J., Tariot P.N., Aisen P.S., Cummings J.L., Vellas B., Sur C., Mukai Y., Voss T., Furtek C., et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 2018;378:1691\u20131703. doi: 10.1056/NEJMoa1706441.", "ArticleIdList": ["10.1056/NEJMoa1706441", "PMC6776074", "29719179"]}, {"Citation": "Selkoe D.J. Resolving controversies on the path to Alzheimer\u2019s therapeutics. Nat. Med. 2011;17:1060\u20131065. doi: 10.1038/nm.2460.", "ArticleIdList": ["10.1038/nm.2460", "21900936"]}, {"Citation": "Sabbagh M.N. Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer\u2019s Disease Suggest Disease Modification. J. Prev. Alzheimer\u2019s Dis. 2017;4:136\u2013137.", "ArticleIdList": ["PMC5724794", "29182703"]}, {"Citation": "Ostrowitzki S., Lasser R.A., Dorflinger E., Scheltens P., Barkhof F., Nikolcheva T., Ashford E., Retout S., Hofmann C., Delmar P., et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 2017;9:95. doi: 10.1186/s13195-017-0318-y.", "ArticleIdList": ["10.1186/s13195-017-0318-y", "PMC5723032", "29221491"]}, {"Citation": "Cummings J.L., Cohen S., Van Dyck C.H., Brody M., Curtis C., Cho W., Ward M., Friesenhahn M., Brunstein F., Quartino A., et al. A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90:E1889\u2013E1897. doi: 10.1212/WNL.0000000000005550.", "ArticleIdList": ["10.1212/WNL.0000000000005550", "PMC5962917", "29695589"]}, {"Citation": "Salloway S.P., Sperling R., Fox N.C., Sabbagh M.N., Honig L.S., Porsteinsson A.P., Rofael H., Ketter N., Wang D., Liu E., et al. Long-term follow up of patients with mild-to-moderate Alzheimer\u2019s disease treated with bapineuzumab in a Phase III, open-label, extension study. J. Alzheimer\u2019s Dis. 2018;64:689\u2013707. doi: 10.3233/JAD-171157.", "ArticleIdList": ["10.3233/JAD-171157", "29914022"]}, {"Citation": "Ketter N., Brashear H.R., Bogert J., Di J., Miaux Y., Gass A., Purcell D.D., Barkhof F., Arrighi H.M. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer\u2019s Disease Patients. J. Alzheimers. Dis. 2017;57:557\u2013573. doi: 10.3233/JAD-160216.", "ArticleIdList": ["10.3233/JAD-160216", "28269765"]}, {"Citation": "ClinicalTrials.gov  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants with Alzheimer\u2019s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.  [(accessed on 30 July 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04241068."}, {"Citation": "ClinicalTrials.gov  A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer\u2019s disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02565511."}, {"Citation": "ClinicalTrials.gov  Safety and Efficacy Study of Gantenerumab in Participants with Early Alzheimer\u2019s Disease (AD)  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03443973."}, {"Citation": "ClinicalTrials.gov  Efficacy and Safety Study of Gantenerumab in Participants with Early Alzheimer\u2019s Disease (AD)  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03444870."}, {"Citation": "ClinicalTrials.gov  Clinical Trial of Solanezumab for Older Individuals Who May Be at Risk for Memory Loss.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02008357."}, {"Citation": "ClinicalTrials.gov  An Efficacy and Safety Study of Sodium Oligo-Mannurarate (GV-971) Capsule for the Treatment of Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02293915."}, {"Citation": "ClinicalTrials.gov  A Study of Gantenerumab in Participants with Mild Alzheimer Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02051608."}, {"Citation": "ClinicalTrials.gov  A Study to Evaluate Albumin and Immunoglobulin in Alzheimer\u2019s Disease.  [(accessed on 3 August 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01561053."}, {"Citation": "Doig A.J., Del Castillo-Frias M.P., Berthoumieu O., Tarus B., Nasica-Labouze J., Sterpone F., Nguyen P.H., Hooper N.M., Faller P., Derreumaux P. Why Is Research on Amyloid-\u03b2 Failing to Give New Drugs for Alzheimer\u2019s Disease? ACS Chem. Neurosci. 2017;8:1435\u20131437. doi: 10.1021/acschemneuro.7b00188.", "ArticleIdList": ["10.1021/acschemneuro.7b00188", "28586203"]}, {"Citation": "Selkoe D.J. Alzheimer disease and aducanumab: Adjusting our approach. Nat. Rev. Neurol. 2019;15:365\u2013366. doi: 10.1038/s41582-019-0205-1.", "ArticleIdList": ["10.1038/s41582-019-0205-1", "31138932"]}, {"Citation": "Livingston G., Sommerlad A., Orgeta V., Costafreda S.G., Huntley J., Ames D., Ballard C., Banerjee S., Burns A., Cohen-Mansfield J., et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673\u20132734. doi: 10.1016/S0140-6736(17)31363-6.", "ArticleIdList": ["10.1016/S0140-6736(17)31363-6", "28735855"]}, {"Citation": "Butterfield D.A., Di Domenico F., Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim. Biophys. Acta Mol. Basis Dis. 2014;1842:1693\u20131706. doi: 10.1016/j.bbadis.2014.06.010.", "ArticleIdList": ["10.1016/j.bbadis.2014.06.010", "PMC4125611", "24949886"]}, {"Citation": "Arnold S.E., Arvanitakis Z., Macauley-Rambach S.L., Koenig A.M., Wang H.Y., Ahima R.S., Craft S., Gandy S., Buettner C., Stoeckel L.E., et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nat. Rev. Neurol. 2018;14:168\u2013181. doi: 10.1038/nrneurol.2017.185.", "ArticleIdList": ["10.1038/nrneurol.2017.185", "PMC6098968", "29377010"]}, {"Citation": "Mielke J.G., Wang Y.T. Progress in Molecular Biology and Translational Science. Vol. 98. Academic Press; Cambridge, MA, USA: 2011. Insulin, synaptic function, and opportunities for neuroprotection; pp. 133\u2013186.", "ArticleIdList": ["21199772"]}, {"Citation": "Chiu S.L., Chen C.M., Cline H.T. Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In Vivo. Neuron. 2008;58:708\u2013719. doi: 10.1016/j.neuron.2008.04.014.", "ArticleIdList": ["10.1016/j.neuron.2008.04.014", "PMC3057650", "18549783"]}, {"Citation": "De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer Disease. Diabetes. 2014;63:2262\u20132272. doi: 10.2337/db13-1954.", "ArticleIdList": ["10.2337/db13-1954", "24931033"]}, {"Citation": "Yarchoan M., Arnold S.E. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014;63:2253\u20132261. doi: 10.2337/db14-0287.", "ArticleIdList": ["10.2337/db14-0287", "PMC4066335", "24931035"]}, {"Citation": "Bruehl H., Sweat V., Hassenstab J., Polyakov V., Convit A. Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance. J. Clin. Exp. Neuropsychol. 2010;32:487\u2013493. doi: 10.1080/13803390903224928.", "ArticleIdList": ["10.1080/13803390903224928", "PMC3116728", "20524222"]}, {"Citation": "Benedict C., Grillo C.A. Insulin resistance as a therapeutic target in the treatment of Alzheimer\u2019s disease: A state-of-the-art review. Front. Neurosci. 2018;12:215. doi: 10.3389/fnins.2018.00215.", "ArticleIdList": ["10.3389/fnins.2018.00215", "PMC5932355", "29743868"]}, {"Citation": "Batista A.F., Forny-Germano L., Clarke J.R., Lyra e Silva N.M., Brito-Moreira J., Boehnke S.E., Winterborn A., Coe B.C., Lablans A., Vital J.F., et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J. Pathol. 2018;245:85\u2013100. doi: 10.1002/path.5056.", "ArticleIdList": ["10.1002/path.5056", "PMC5947670", "29435980"]}, {"Citation": "Craft S., Claxton A., Baker L.D., Hanson A.J., Cholerton B., Trittschuh E.H., Dahl D., Caulder E., Neth B., Montine T.J., et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer\u2019s Disease Biomarkers: A Pilot Clinical Trial. J. Alzheimer\u2019s Dis. 2017;57:1325\u20131334. doi: 10.3233/JAD-161256.", "ArticleIdList": ["10.3233/JAD-161256", "PMC5409050", "28372335"]}, {"Citation": "Abbott A. Is \u201cfriendly fire\u201d in the brain provoking Alzheimer\u2019s disease? Nature. 2018;556:426\u2013428. doi: 10.1038/d41586-018-04930-7.", "ArticleIdList": ["10.1038/d41586-018-04930-7", "29691517"]}, {"Citation": "Salter M.W., Stevens B. Microglia emerge as central players in brain disease. Nat. Med. 2017;23:1018\u20131027. doi: 10.1038/nm.4397.", "ArticleIdList": ["10.1038/nm.4397", "28886007"]}, {"Citation": "Bu X.L., Yao X.Q., Jiao S.S., Zeng F., Liu Y.H., Xiang Y., Liang C.R., Wang Q.H., Wang X., Cao H.Y., et al. A study on the association between infectious burden and Alzheimer\u2019s disease. Eur. J. Neurol. 2015;22:1519\u20131525. doi: 10.1111/ene.12477.", "ArticleIdList": ["10.1111/ene.12477", "24910016"]}, {"Citation": "Fani L., Wolters F.J., Ikram M.K., Bruno M.J., Hofman A., Koudstaal P.J., Darwish Murad S., Ikram M.A. Helicobacter pylori and the risk of dementia: A population-based study. Alzheimer\u2019s Dement. 2018;14:1377\u20131382. doi: 10.1016/j.jalz.2018.05.005.", "ArticleIdList": ["10.1016/j.jalz.2018.05.005", "29935141"]}, {"Citation": "Marsh S.E., Abud E.M., Lakatos A., Karimzadeh A., Yeung S.T., Davtyan H., Fote G.M., Lau L., Weinger J.G., Lane T.E., et al. The adaptive immune system restrains Alzheimer\u2019s disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. USA. 2016;113:E1316\u2013E1325. doi: 10.1073/pnas.1525466113.", "ArticleIdList": ["10.1073/pnas.1525466113", "PMC4780638", "26884167"]}, {"Citation": "Congdon E.E., Sigurdsson E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018;14:399\u2013415. doi: 10.1038/s41582-018-0013-z.", "ArticleIdList": ["10.1038/s41582-018-0013-z", "PMC6463489", "29895964"]}]}], "History": [{"Year": "2020", "Month": "7", "Day": "20"}, {"Year": "2020", "Month": "8", "Day": "3"}, {"Year": "2020", "Month": "8", "Day": "12"}, {"Year": "2020", "Month": "8", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "2", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["32824102", "PMC7461598", "10.3390/ijms21165858", "ijms21165858"]}}]}